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 i 
Résumé 
Introduction : La néphrotoxicité est une complication majeure de la gentamicine, qui est 
largement utilisée dans le traitement des infections bactériennes, en particulier celles 
provoquées par des bactéries à Gram-négatif. La gentamicine induit l'apoptose tubulaire, mais 
les mécanismes moléculaires impliqués demeurent mal compris. Dans l’étude présente, nous 
avons examiné le rôle des espèces réactives de l'oxygène (ROS) , des  proteins Bax,  Bmf et 
Caspase-12 (Csp-12) dans le mécanisme d’action de la gentamicine sur l'apoptose des tubules 
proximaux rénaux (RPT) et les dommages rénaux induits par ce médicament chez la souris. 
Méthode: Des souris adultes (âgées 18-19 semaines) mâles non-Tg et des souris transgéniques 
(CAT-Tg) qui surexpriment la catalase spécifiquement dans leurs cellules des RPT ont été 
traitées par injections intra-péritonéales de gentamicine (20 mg/kg/jour) pour 5 jours 
consécutifs, puis euthanasiés. Les reins ont été examinés et analysés par  histologie, 
immunohistochimie pour presansance de la stress oxidative, expression des proteins Bax, Bmf 
et Csp-12 et essai TUNEL  pour étudier de l’apoptose . Nous avons aussi examiné l'effet de la 
gentamicine sur  génération des ROS et l’apoptose dans les cellules RPTC 
immortalisées de rat (IRPTC) in vitro. 
Résultats: In vivo, chez les souris non-Tg, la gentamicine induit une tubulopathie et l'apoptose 
des RPT , stimule la production de ROS et induit une augmentation de Bax et Bmf détectée 
par immunohistochimie et augmont activité du caspase-12. Ces changements sont atténués 
chez les souris Cat-Tg. In vitro, la gentamicine induit l’apoptos des cellulles. Le co-traitement 
avec la catalase normalise ces effets dans les IRPTC.  
Conclusion : Ces données démontrent que l'apoptose des RPTC induite par la gentamicine 
s’effectue, au moins en partie, par l'intermédiaire de la génération des ROS. 
Mots-clés : gentamicine, néphrotoxicié, apoptos, ROS, catalase   
 ii 
Abstract 
Catalase (Cat) Overexpression Prevents Gentamicin-induced Renal Proximal Tubular 
Apoptosis in Transgenic mice  
Background: Nephrotoxicity is a major complication of gentamicin, which is widely used in 
the treatment of severe gram-negative infections. Gentamicin promotes tubular apoptosis, but 
the mechanisms by which this occurs are incompletely understood. In the present study, we 
investigated whether the underlying mechanism(s) of gentamycin-induced renal proximal 
tubular (RPT) apoptosis is mediated, at least in part, via reactive oxygen species (ROS) 
generation in mice. 
Methods: Adult (age 18-19 weeks) male non-Tg mice and transgenic (Tg) mice specifically 
overexpressing catalase (Cat) in their renal proximal tubular cells (RPTCs) were administered 
i.p. with gentamicin (20mg/kg/days) for five days consecutively and then euthanized at two 
different time point. Kidneys were processed for morphological analysis, apoptosis study 
(TUNEL assay), presence of increased ROS generation, immunostaining for Bax, Bmf and 
Casp12 proteins and Casp12 activity. We also examined the effect of gentamicin on apoptosis 
in immortalized rat RPTCs in vitro. 
Results: In vivo, gentamicin induced significant tubular apoptosis, ROS generation, increased 
expression of Bax and Bmf proteins and Casp12 activity in non-Tg mice. Most of these 
changes were normalized in Cat-Tg mice..In vitro, gentamicin induced apoptosis of iRPTCs 
while co-treatment with Cat increased cells viability and reduced apoptosis of the cells. 
Conclusions: These data demonstrate that gentamicin-induced RPTC apoptosis is 
mediated, at least in part, via ROS generation. 
 
Keywords: gentamicin,  nephrotoxicity,  apoptos,  ROS,  catalase 
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I. INTRODUCTION.  
 I.1. Kidney anatomy. 
  I.1.1. Gross anatomy and function. 
    I.1.1.1. Topography and structure of the kidneys. 
The kidneys are paired bean-shaped organs, which play an essential role in human and (most) 
animal  and are important part of urinary systems. Kidneys regulate fluid and electrolyte 
balance, participate in maintaining blood pressure, remove body wastes and also work as an 
endocrine organ by producing erythropoietin and vitamin D. 
In humans, the kidneys are located in the retroperitoneum, between the transverse processes of 
T12–L3 vertebrae. The upper poles of the kidney are oriented more medially and posteriorly 
than the lower poles, the left kidney usually somewhat more superior than the right one. In the 
medial part of the kidney there is a hilum-central kidney fissure, which is a gate for the blood 
and lymphatic vessels and ureter. 
 
Figure 1.Kidney gross anatomical location (source: Gray’s anatomy Online). 
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The kidney is surrounded by the renal capsule – fibrous tissue, and on the top of it 
with perinephric fat, renal and paranephric fat. These multiple layers provide amortisation and 
protect the kidneys from physical injury. If we make a longitudinal cut of the kidney we can 
see that the kidney’s parenchyma has a particular structure and is divided into two visibly 
different parts — the external renal cortex and the internal renal medulla. The medulla consists 
of 8 to18 red-coloured striated conical masses called the renal pyramids. Their bases are 
directed toward the circumference of the kidney, while their apices converge toward the renal 
sinus, forming the tip of pyramid — papilla. The cortex, reddish brown in colour and soft, 
arches over the bases of the pyramids and project in between adjacent pyramids toward the 
renal sinus. The parts dipping in between the pyramids are called the renal columns. There is 
also a central cavity that starts its formation from the kidney hilum and is called renal sinus. 
The renal sinus contains 7 to 13 minor renal calyces — cup-shaped tubes, each of which 
embraces one or more of the renal papilla. Renal calyces unite to form two or three short tubes 
—major renal calyces — and these in turn join to form a funnel-shaped sac, the renal 
pelvis. The renal pelvis, joins the ureter [1]. 
 
Copyright © 2004 Pearson Education, Inc., publishing as Benjamin Cummings 
Figure 2. Sectional anatomy of the kidneys (diagrammatic view and photograph). 
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I.1.1.2. Kidney’s vasculature and renal lymphatics. 
The kidneys receive the blood supply from the paired renal arteries which arise at the level of 
the L2 vertebra from the abdominal aorta. The kidneys receive approximately 20% of cardiac 
output. This number shows how important these organs are for the proper functioning of the 
body and explains why the kidney are so susceptible to ischemia in the case of volume loss 
and a drop in systemic blood pressure. Inside the kidneys the renal artery branches off into 
four to five segmental branches, three of which branch further into intralobar arteries and then 
into arcuate arteries. The arcuate arteries run along the border of the renal cortex and renal 
medulla across the bases of the renal pyramids .They then radiate into interlobular arteries to 
become afferent arterioles, then peritubular capillaries and subsequently efferent arterioles. 
Another two branches, originated from the renal artery, supply the upper portion of the 
collecting system. 
The renal veins drain the kidneys and carry the blood for them to the inferior vena cava (IVC). 
They have a similar distribution pattern as renal arteries. The left renal vein is longer than the 
right and usually receives suprarenal, gonadal, lumbar and inferior phrenic veins, while the 
right-side veins drain directly into the IVC.  
The lymphatic drainage parallels the venous vessels and drains the lymph into the left lateral 
aortic lymph nodes and right caval lymph nodes [2]. 
 
Copyright © 2004 Pearson Education, Inc., publishing as Benjamin Cummings 
Figure 3. Renal blood supply. 
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I.1.1.3. Renal innervations. 
The kidney receives autonomic supply via both the sympathetic and parasympathetic portions 
of the nervous system. The preganglionic sympathetic nervous innervation to the kidneys 
comes from the spinal cord at the level of T5-T9. Preganglionic neurons synapse onto the 
celiac and aortico-renal ganglia and follow the plexus of nerves that runs with the arteries. 
Activation of the sympathetic system causes vasoconstriction of the renal vessels. 
Parasympathetic innervation arises from the 10th cranial nerve, also called vagus nerve, and 
causes vasodilatation when stimulated. 
 
Figure 4. Autonomic innervations of adrenal gland (A) and kidney (B). 
Red=sympathetic and Blue=parasympathetic innervations. (source: from what-when-how.com 
Chapter “ The Autonomic nervous system (Integrative systems).Part3.[3]  
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I.1.2. Microscopic Anatomy. 
 I.1.2.1. Nephron – microscopic functional unit of the kidneys. 
The kidney has complicated but amazing microstructure. The functional renal unit is the 
nephron which is composed of the following: 
• The renal corpuscle: glomerulus and Bowman capsule 
• Proximal convoluted tubules (PCTs, located in the renal cortex) 
• Descending loop of Henle (LOH) 
• Ascending limb (resides in the renal medulla, leading to the thick ascending limb) 
• Thick ascending limb 
• Distal convoluted tubule 
• Collecting duct (which opens into the renal papilla) 
  Each kidney contains around 1 million individual nephrons. 
 
 
Copyright © 2004 Pearson Education, Inc., publishing as Benjamin Cummings 
Figure 5. Nephron structure (b) with close look to the glomerular (c) and podocytes(d). 
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The glomerulus is a network of capillaries, which forms from the afferent arteriole. These 
capillaries filter the blood. The proper filtration is achieved thanks to the 3-level barrier, which 
contains endotheliocytes, basal membrane and podocytes — specific renal epithelial cells. 
This filtrate reaches the proximal convoluted tubules (PCTs) where the process of reabsorption 
and secretions happen. Meanwhile the blood, after being filtrated, passes into the efferent 
arteriole and then descends into the renal pyramid. 
The renal tubules present many changes in their shape and morphology during their course. 
Proximal tubules start with convoluted portion from glomerular capsule, forming the 
glomerulo-tubular junction. When PCTs approach the medulla they turn into straight tubules, 
and when they dip down into the medulla they become smaller in diameter and straighten in 
direction; these tubules called descending limb of Henle’s loop. Bending on themselves, they 
form what is termed the loop of Henle. After the tubules reascend and become enlarged, 
forming the ascending limb of Henle’s loop, which re-enters the cortex. This portion of the 
tubule ascends in the cortex only for a short distance and becomes again enlarged and 
convoluted; forming distal convoluted tubules (DCTs). DCTs progress into collecting ducts, 
which dip down to the medullar, converge inside of each pyramids and open on the summit of 
the papilla. 
I would like to pay more attention to the structure of the renal tubules, and proximal tubules 
(PT) in particular, since in our study we concentrate on the pathological changes in this part of 
the nephron.  
I.1.2.2. Renal proximal tubules. 
All renal tubules consist of basal membrane lined with epithelium. The epithelium varies 
considerably in different section of the tubules according to the function of each part of the 
renal tubular system. The main function of PT is reabsorption and this explains their 
particularities. The length of PT is several times greater than DCT, so in a typical histological 
slide sections of the renal cortex PT are much more prominent. The proximal tubule has been 
divided into two portions by morphology and function: the proximal convoluted portion (pars 
convoluta, PCT), which occupies the cortical labyrinth, and the straight portion (pars recta), in 
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the medullary rays of the cortex and outer medulla. Another classification system has divided 
proximal tubules in three portions: S1, S2 and S3, where pars convoluta (PCT) correspond to 
S1 and the first part of S2. PCT lined with simple cuboidal epithelium which has several 
characteristic features. The apical end of the cells has a brush-border of microvilli, which 
increase a total surface of PCT and accommodate multiple receptors for absorption of water, 
salt and different elements. On the histology section it is rare to see the intact brush-border, 
since it is usually lost during the cutting. However, overall the apical end of the cell remains 
preserved, which makes PCTs, together with size and shape, easily distinguishable from all 
other kind of tubules. The cells of PCT have a higher proportion of mitochondria in order to 
provide enough energy for multiple pumps and receptors. The increased number of 
mitochondria makes them highly acidophilic which means that they are stained more intensely 
compared to DCT. On the stained histology section the boundaries between adjacent epithelial 
cells of PCT are inconspicuous, and in turn the epithelium looks like a continuous band of 
cytoplasm with nuclei at irregular intervals. The reason for this phenomenon is that the plasma 
membranes of these cells are extremely interdigitated, again in order to optimise reabsorption 
[4].  
Transition of S1 to S2 is gradual and evidenced by a diminution in the structural complexity. 
The cells become more cubic and there are fewer and shorter microvilli. There is also 
interdigitation only in the lateral bases of the cells, and mitochondria diminish in number and 
size. In S3 the epithelium is simple cubical, the microvilli are smaller and still fewer in 
number; there are more peroxisomes and a less developed endocytic apparatus [5]. 
I. 2. Gentamicin-induced nephrotoxicity. 
   I.2.1. Pharmacological characteristics of gentamicin. 
      I.2.1.1. Antimicrobial activity and mechanism of action. 
Gentamicin is an antibiotic of the aminoglycoside class. This class of antibiotics consists of 
many different agents with gentamicin, tobramycin, and amikacin being the most frequently 
prescribed medications. 
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The aminoglycosides primarily act by binding to the aminoacyl site of 16S ribosomal RNA 
within the 30S bacterial ribosomal subunit, leading to misreading of the genetic code. 
Misreading occurs possibly via reduced rejection rate for tRNAs that are near matches for the 
codon and this, in turn, alter protein translation [6, 7]. The bacterial peptide synthesis becomes 
inaccurate, often with premature termination, despite the fact that initial steps of peptide 
synthesis, such as the binding of mRNA and the association of the 50S ribosomal subunit, are 
uninterrupted [6].  
 
Copyright © Gary E. Kaiser  
Figure 6. Aminoglycosides mechanism of action. Source: from Doc. Kaiser’s Microbiology 
[8] 
This particular mechanism explains some alternative usage of aminoglycosides for improving 
mutated protein function in some genetic diseases with premature stop-codon in the affected 
protein.  . I will discuss this topic in more detail later in the thesis. 
Aminoglycosides antimicrobial activity is usually bactericidal against susceptible aerobic 
gram-negative bacilli. The most common clinical application of aminoglycoside antibiotics is 
in the treatment of serious infections caused by aerobic gram-negative bacilli [9]. Often 
aminoglycosides are used in combination with antibiotics of other classes. The advantage of 
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the aminoglycoside class is their relative stability against the development of resistance. 
Treatment-emergent resistance when used in combination with other agents is rare. However, 
aminoglycosides are usually used as a second-line treatment because of the major side effects, 
ototoxicity and nephrotoxicity. 
I.2.1.2. Pharmacokinetics and pharmacodynamics of gentamicin. 
Gentamicin is a polycationic drug, a property that is responsible for its poor oral absorption, 
poor penetration into cerebrospinal fluid (CSF) and rapid renal clearance. Gentamicin is used 
only parenterally. It was shown that higher doses, administered once daily, demonstrated 
pharmacokinetic difference compared with lower multiple doses by making the distribution 
phase very prominent [10]. There are also some pharmacodynamic properties of gentamicin 
that make single daily dosing as effective as multiple dosing. The medication has 
concentration-dependent kill characteristics and significant post-antibiotic effect. The latter 
property means that inhibition of bacterial growth continues for hours despite gentamicin 
concentrations falling below the minimum inhibitory concentration [11]. 
Volume of distribution of gentamicin is low. Gentamicin has good penetration to several body 
fluids including synovial ﬂuid, peritoneal, ascitic, and pleural ﬂuids, but poor penetration into 
the central nervous system and the vitreous. Gentamicin distributes quite slowly into bile, 
feces, prostate, and amniotic ﬂuid [12, 13]. Serum protein binding of gentamicin is less than 
10%.  Gentamicin is freely filtered across the glomerulus; almost all the drug is then excreted. 
Clearance is substantially reduced in the settings of poor kidney function; it is also reduced in 
healthy elderly people and neonates because of physiologically reduced glomerular filtration 
in these categories of patients. Nephrotoxicity of the gentamicin is explained by the fact that 
5% - 10% of a parenteral dose is being taken up and sequestered by the proximal tubule cells 
where the drug can achieve concentrations vastly exceeding the concurrent serum 
concentration. The serum half-life of gentamicin is a few hours as compared to four to five 
days in proximal tubule cells. 
The intracellular accumulation of aminoglycosides is confined primarily to the S1 and S2 
segments of the proximal tubule. However, following renal ischemia, the S3 portion is also a 
site of intracellular aminoglycoside concentrations. Gentamicin uptake into the tubular 
 10 
epithelium is saturable which means that the increasing luminal concentrations that occur with 
higher doses of the drug do not obligatorily result in greater rates of uptake and greater tubular 
damage [14] . Here we return to a once-daily dosing regimen which was discovered not only to 
be effective but also safer than multiple daily doses. Gilbert et al. [15] hypothesized that the 
fact of saturation of tubular uptake can make higher once-daily dosing safer because it will not 
increase the uptake but at the same time will provide additional period for the gentamicin to 
leach back from the cells into the lumen.  Studies in rabbits and dogs have supported this 
theory by showing that aminoglycosides are more nephrotoxic when the same total daily dose 
is given in divided doses or by continuous infusion [14] . The same finding was later proved 
for humans as well. In one study researchers showed that renal cortical concentration of 
gentamicin and netilmicin given as a single daily dose was 30%50% lower compared with 
treatment at the same dose but by continuous infusion; another prospective clinical study 
demonstrated that continuous infusion of aminoglycosides caused a more rapid onset of 
nephrotoxicity[16, 17] [18] . These pharmacokinetic particularities explain the difficulty of 
prevention of gentamicin-induced nephrotoxicity since acute kidney injury can occur even if 
drug levels are closely monitored [19].  
I.2.2. Incidence, clinical manifestations and laboratory findings in 
gentamicin-induced AKI. 
Aminoglycoside-related nephrotoxicity occurs in 10%–30% of patients receiving 
aminoglycosides, even when blood levels are in apparently therapeutic ranges. There are 
certain risk factors that increase the risk of nephrotoxicity and its severity, including liver 
diseases, pre-existing renal disease, simultaneous use of other nephrotoxins (e.g., amphotericin 
B, radiocontrast media, cisplatin), advanced age and being female [20].                          
Patients with aminoglycoside nephrotoxicity usually present with nonoliguric or even polyuric 
renal failure and elevation in serum creatinine. The usual onset of clinical symptoms and 
laboratory abnormalities occurs following 7 to 10 days of therapy [21, 22]  
Apart from elevated serum creatinine, which is considered to be the main clinical marker of 
acute kidney injury (AKI) , urinalysis shows an elevated fractional excretion of sodium 
(FENa), accompanied by wasting of potassium, calcium, and magnesium. Enzymuria, one of 
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the characteristic signs of AKI, is induced by aminoglycosides and results from intracellular 
lysosome damage of the PCT epithelial cells. Enzymuria is a very specific and early marker of 
aminoglycoside tubular damage; laboratory tests for measuring it are, accordingly, expensive 
and impractical in clinical routine, but can be used in research. 
1.2.3. Macro- and microscopic morphologic changes in gentamicin-induced 
AKI. 
Animal studies allowed us to get a deeper insight into gentamicin nephrotoxicity and to 
disclose macro and micro patho-morphological changes in kidneys damaged by gentamicin 
treatment. In the study by Feyissa et al. in 2013 [23] it was shown that rats treated with 
gentamicin 100mg/kg for eight days had experienced severe body weight loss by the end of 
the treatment. On the autopsy , which was done within 24 hours of the last injection, the 
kidneys of treated animals were found to be slightly bigger compared to those of the control 
group (kidney weight was normalized to body weight). The authors explained body weight 
loss by dehydration and anorexia due to acidosis. They suggested that increased normalized 
kidney weight in treated animals might be explained by kidney edema due to necrosis. 
Morphological changes in the kidney affected by aminoglycosides are well described and are 
very consistent from study to study. The most dramatic changes are observed in the proximal 
tubules, particularly in the S1 and S2 segments. Proximal tubular cell death either via 
apoptosis or necrosis is the most characteristic feature of aminoglycoside – induced 
nephrotoxicity [24, 25]. 
 The phenotype of cell death depends on the dose of the drug, the level of ischemia, the use of 
other nephrotoxic substances at the same time and the storage of ATP in the cell, since it is 
known that apoptosis is an ATP-requiring process [26-28]. Detached dead tubular cells can be 
seen in the lumina of some renal tubules. Surviving epithelial cells undergo hydropic changes 
with vacuolization of the cytoplasm and lose their brush-border. Distention and deformation of 
PCTs can  also be present (see Figure 7). 
In the study by El Moudden et al, 2000 [25], rats were treated with low doses of gentamicin 
(10–20 mg/kg), very close to the doses used in humans, but with a twice-daily schedule of 
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injections. Even at a dose of 10 mg/kg used for 10 days a clear-cut phospholipidosis and 
marked apoptotic cell death of PCT were present without any other elevation of AKI markers 
such as creatinine and BUN and there were no signs of tubular necrosis (see Figure 8). These 
data allow us to suggest that in all patients treated with gentamicin for long enough there is 
some kidney damage, even in cases when there is no clinically overt AKI syndrome. 
 
 
Figure 7. Pathomorphological changes in kidneys, affected by gentamicin treatment. 
Dilated tubules, detached tubular cells and epithelial casts in the tubular lumen [23] 
 
There were minor morphological changes in other parts of the nephron. The glomeruli showed 
mild hypercellularity and congestion in most of the sections. The renal interstitium showed 
infiltration by polymorphonuclear leukocytes, lymphocytes, plasma cells and macrophages, 
particularly around the necrotic tubules. The renal vascular changes were limited to focal 
congestion only [29]. 
The most commonly observed phenotype in vitro is apoptosis. It has been shown in many 
studies that, in vitro, relatively high doses of gentamicin (>12 mg/ml) are required in order to 
induce significant effect on renal cells [30-32]. It was also  demonstrated that even with these 
high doses there is almost no necrosis and cell death occurs predominantly via apoptosis  [32]. 
 
Recovery from aminoglycoside nephrotoxicity is usually slow, taking about four to six weeks, 
particularly in elderly patients. Although the vast majority of patients do recover, the presence 
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of several risk factors, mentioned above, may affect the natural course of the nephrotoxicity. 
In these cases, acute kidney failure may start early after the treatment and could be very 
severe; recovery might be long and incomplete [33] 
 
 
Figure 8. Light microscopy appearance of paraffin sections of rat kidney cortex.  
Sections stained with hematoxylin and eosin (A and C) and with methyl green-pyronine (B 
and D). Animals were treated with gentamicin for 10 days (10 [A and B] or 20 [C and D] 
mg/kg). Single arrows point to cells showing clear evidence of nuclear alterations related to 
apoptosis; the double arrowhead (in panel C) shows a cell with clear shrinkage and 
eosinophilia of the cytoplasm; NT (in panel C) denotes a necrotic tubule. Two mitotic figures 
are circled in panels B and D. [25] 
 
In spite of being one of the most nephrotoxic drugs among aminoglycosides [15, 34, 35] 
gentamicin is still frequently used in a vast variety of clinical situations. Moreover, this 
particular aminoglycoside has been widely used as a model to study the nephrotoxicity of this 
family of drugs, in experiments involving both animals and human beings. Most of the 
available data on the mechanisms responsible for aminoglycoside nephrotoxicity have been 
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obtained from gentamicin studies, especially at the preclinical level, in animal models or cell 
culture studies.  
I.2.4. Molecular mechanisms of gentamicin-induced tubular damage. 
Many mechanisms and pathways of gentamicin-induced intracellular damage of tubular cells 
have already been elucidated by various studies. However, the hierarchic relation among them 
is still unknown, as is the contribution of each particular pathway in different circumstances. 
These questions prompted us to conduct further research. 
I.2.4.1. Mechanism of gentamicin cellular uptake. The role of the megalin-cubulin 
complex. 
Gentamicn accumulates in the proximal tubules via a special membrane endocytic complex 
involving mambrane proteins megalin and cubulin [36-38].  
Megalin is a 600-kDa transmembrane protein belonging to LDL-receptor family[39]. [39]. 
The complete cDNA sequences have been characterized for rat [40] and human megalin [41]. 
Cubilin is a 460-kDa peripheral membrane protein. Its structure is identical to the intrinsic 
factor-vitamin B12 receptor found in the small intestine. Cubulin’s primary sequence, 
determined in rat, man and canine [42-44], is conserved with an overall homology of 69% 
between rat and human cubilin and 83% between canine and human cubilin. Membrane 
association of cubulin depends on the 110 amino acid at the N-terminus [45]. Previous data 
suggest that the internalization of cubilin is, at least in part, carried out by megalin [42, 46] 
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Figure 9. Schematic presentation of the two endocytic receptors, megalin and cubulin 
[47]. CP- Coated Pits. 
Megalin is expressed in many epithelial cells, while cubulin expression seems more restrictive 
[48]. The two receptors are co-localized in the proximal tubule, the small intestine, the visceral 
yolk sac and the cytotrophoblast of the placenta. This megalin-cubulin complex transports 
cations present in the ultrafiltrate,  such as a vast variety of proteins and certain xenobiotics, as 
for example aminoglycoside antibiotics [49]. The studies done on megalin-deficient mice and 
dogs lacking functional cubulin have shown that both receptors are important for normal 
reabsorption of proteins in PT since these type of animals developed severe proteinuria [50, 
51]. It was shown as well that megalin deficiency prevents the accumulation of gentamicin in 
PT cells in mice. [49]. 
I.2.4.2. Gentamicin intracellular migration. 
Many animal studies and in vitro studies allowed us to have a better understanding of 
gentamicin intracellular trafficking. As discussed above, most gentamicin enters the PT cells 
via endocytosis mediated by the megalin/cubulin complex and  then passes via pinocytosis to 
the endosomal compartment. A small amount of gentamicin can enter the cytosol and nucleus 
of tubular cells directly and independently from megulin/cubulin endocytosis[52, 53]. In distal 
tubules this gentamicin entry is realized probably through an unspecific cation channel, 
namely the transient receptor potential vanilloid type 4 channel [52]. However, the exact role 
of this entry mechanism is unclear. 
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Figure 10. Mechanism of uptake and subcellular redistribution of gentamicin in tubular 
and other renal cells.  
Source  [54]. M-megalin-cubulin complex; CaSR- calcium-sensing receptor. 
After the entry into the PT cell, the drug mostly accumulates in the lysosomes, travels 
retrograde through the secretory pathway to the Golgi complex and endoplasmic reticulum 
(ER) [55, 56]. On the way of its deadly trip, gentamicin alters the function of cellular 
organelles. In the lysosomes, the drug causes membrane destabilization, alteration of lipid 
metabolism, and phospholipidosis [57]. Gentamicin disturbs vesicular traffic while passing 
through Golgi [58, 59] and can originate ER stress when accumulating in ER. The outcome for 
the cell depends on intracellular gentamicin concentration and the metabolic status of the 
affected cell. Cells in hypoxic condition and cells lacking ATP are more susceptible to damage 
and more likely to die [60, 61]. 
Mechanisms and pathways involved in gentamicin-induced cell death include the following: 
ER stress and unfolded protein response (UPR), probably with activation of the caspase-12 / 
calpain pathway; direct and indirect mitochondrial effect; oxidative stress and production of 
reactive oxygen species (ROS); phospholipidosis and massive proteolysis and impairment of 
the cell’s metabolic status and the recently discovered and not yet well established CaSR 
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stimulation pathways.  The summary effect of these pathways, which often overlap, 
determines cell survival and the phenotype of the cell’s death. I will discuss these pathways in 
detail below. 
I.2.5. Intracellular mechanisms and pathways, involved in gentamicin-
induced tubular damage. 
I.2.5.1. Membrane destabilization and phospholipidosis. 
The first intracellular organelles with which gentamicn meets after its entry via 
megalin/cubulin complex are lysosomes. Because of its polycationic properties, gentamicin 
easily binds to phospholipids of membranes and cause cell membrane structure alterations 
[62]- a condition, characterized by an intracellular accumulation of phospholipids and the 
concurrent development of concentric lamellar bodies, known as phospholipidosis. This 
phenomenon has been observed in both- humans [57] and animals treated with the drug [63, 
64] . The mechanisms of phopholipidosis are still not well understood, however some 
mechanisms have been elucidated. Disruption of phosphatidylinositol signaling pathways [65], 
reduction of phospholipid turnover [66] and the available negative charge necessary for the 
correct function of phospholipases [67], and  the inhibition of calcium-dependent 
phosphodiesterases [68] lead to excess of phospholipids inside the cell. In general, it is still 
unclear whether phospholipidosis by itself cause any functional impairment in cells. The only 
circumstance where a causal relationship between the presence of phospholipidosis and tissue 
dysfunction has been suggested is with aminoglycosides and nephrotoxicity. Phospholipidosis 
and phospholipiduria are very characteristic features of gentamicin- induced nephrotoxicity 
however its role in PT cell death remains unclear. Several studies have been done on this 
subject in 90-s. It was shown that lysosomal phospholipidosis correlates tightly with the level 
of toxicity of aminoglycosides [64, 69, 70]. Moreover, in experiments with rats who received 
co-treatment with polyaspartic acid (PAA) it was demonstrated that this substance can 
significantly mitigate or even completely prevent nephrotoxicity of gentamicin[71] . The 
effects of PAA were explained by its capacity to bind with gentamicin and thus prevent its 
union with phospholipids of lysosomal membrane. Here the main controversy comes, because 
gentamicin has to bind with phospholipids of cell membrane in order to entre inside the cell. It 
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means that most probably co-treatment with PAA decrease intracellular gentamicin 
concentration and by this prevents its toxicity. 
Nevertheless it was proven that after exceeding a certain threshold of accumulation rupture of 
lysosomal membrane occurs and lysosomal content along with the drug is poured into the 
cytosol [72]. 
The lysosomal highly active proteases named cathepsins, are capable of producing cell death 
by themselves, inducing apoptosis both directly, by caspases  cleavage [73] and indirectly 
through the activation of Bid, member of Bcl-2 family of proteins [74]. Cathepsins can also 
cause a rapid necrotic-like cell death, when they are present in high amounts, especially under 
the low ATP conditions of the cell.  
 
Figure 11. Cytosolic redistribution of gentamicin and mechanisms leading to cell death 
through necrosis and the apoptotic intrinsic. Source [54] 
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I.2.5.2. ER stress and Unfolded Protein Response. 
  I.2.5.2.1. ER srtucture and function. 
The endoplasmic reticulum (ER) is a central organelle of each eukaryotic cell. It is arranged in 
a dynamic tubular network. ER is divided into two parts: rough endoplasmic reticulum (RER) 
with ribosomes on its cytosolic face, and smooth endoplasmic reticulum (SER) without 
ribosomes. Depending on the cell type, one of the two ER parts dominates. An improved 
staining technique of ER membrane sheets, developed by J. Lichtman and colleagues, brought 
a new insight into the structure of this essential organelle. Applying this new staining method 
to mouse neuron and salivary gland cells, Terasaki and colleagues discovered that ER is a 
continuous membrane system, helicoidal in shape, resembling a spiral staircase. Together with 
ribosomes ER creates a “parking garage” model, which optimizes the dense packing of ER 
and maximizes the number of ribosomes and thus also maximizes protein synthesis.  
 
Figure 12. 3D structure of ER provided by Terasaki et al. Stacked Endoplasmic Reticulum 
Sheets Are Connected by Helicoidal Membrane Motifs. Source: Cell, Volume 154, Issue 2, 285-
296, 18 July 2013)  
ER is involved in different intracellular metabolic processes, such as gluconeogenesis, lipid 
synthesis and detoxification. It is also the major intracellular calcium reservoir. One of the 
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most important functions of ER is protein maturation and protein folding. Proteins of the 
plasma membrane, secreted proteins as well as proteins of the Golgi apparatus and lysosomes 
fold into their tertiary and quaternary structure in the ER. This protein-folding machinery is 
especially developed in specialized secretory cells due to their high activity of protein 
synthesis [75] 
The protein-folding machinery of the ER is an outstanding system for protein maturation and 
constant quality monitoring of the process. It consists of three classes of proteins: foldases, 
molecular chaperones and the lectins. Foldases are enzymes that catalyze folding. Molecular 
chaperones do not enhance the rate of protein folding by themselves but facilitate the process 
by shielding unfolded regions from surrounding proteins and preventing the aggregation of 
immature polypeptides. Molecular chaperones are classified into several groups: class HSP70 
chaperones in the ER are BiP/GRP78/Kar2p, Lhs1p (Cer1p/Ssi1p) and GRP170 [76]  Lectins 
act as a chaperons as well but also have some other functions [77]. Molecular chaperons and 
lectins are the second arm of the quality-control mechanisms in the ER. 
 
Figure 13. The structure of the substrate binding domain of the Hsp70 protein DnaK 
(front and side views, left and center), with a bound peptide (green) in a channel penetrating 
right through the DnaK domain. On the right is the ATPase domain of another member of the 
Hsp70 family, Hsc70. The ATP (space filling) binding site is in a cleft. The ATPase domain 
structure is homologous to those of actin and hexokinase. Source: Molecular Chaperone 
Group [78] 
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I.2.5.2.2. ER stress and Unfolded Protein Response pathways. 
Multiple environmental and cellular signals could interfere with ER functioning and in 
particular with protein traffic and protein folding processes, producing so-called “ER stress.” 
Several intracellular pathways are aimed to maintain homeostasis and adjust for the changes 
and insults. One of the best studied pathways is the unfolded protein response (UPR), which 
helps cells cope with protein-folding alterations by buffering fluctuation in unfolded protein 
load [76, 79]. However, if ER stress is very severe or long enough and it is impossible to save 
the cell, the UPR aims to remove damaged cell. In these cases, the damaged cell undergoes 
elimination via apoptosis to prevent a negative effect on adjacent cells and any further damage 
[80]. Here, I would like give an overview of the UPR signaling for better understanding of the 
gentamicin effect on ER and its consequences. 
I.2.5.2.3. Adaptive programs of UPR. 
Activated, the UPR launches several pro-survival mechanisms, including the selective 
synthesis of key components of protein folding, the expansion of the ER membrane, quality 
control and the attenuation of the protein’s influx into the ER. 
. 
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Figure 14. Scheme of ER stress and UPR induced activation of different pathways. 
Source: Cornell University, division of Nutritional science website [81]. 
These are adaptive mechanisms of the UPR, which, based on our current knowledge, are 
mediated by the activation of at least three major stress sensors: IRE1 (both α and β isoforms), 
activating transcription factor 6 (ATF6) (both α and β isoforms) and protein kinase RNA-like 
ER kinase (PERK) [82]. 
Activation of PERK pathways inhibits protein translation by phosphorylation of eukaryotic 
translation initiator factor  2α (eIF2α) [83]. IRE1-dependent decay initiates selective 
degradation of mRNA, encoding for certain ER-located proteins [84-86]. Some of the proteins 
are not able to translocate into ER upon their translation thanks to pre-emptive quality control 
and cotranslational degradation [87] initiated by the UPR. Activation of the lysosomal 
pathway induces macroautophagy, possibly to eliminate damaged ER and abnormal protein 
aggregates [88]. Overall, the above mechanisms decrease protein influx into ER, unload ER 
and allow it to restore homeostasis. Phosphorylation of eIF2α by PERK also leads to the 
 23 
selective translation of the mRNA, encoding the transcription factor ATF4, which controls 
pro-survival genes and autophagy [76, 89]. 
The IRE1α pathway under the condition of ER stress processes the mRNA, encoding the 
transcription factor X-box binding protein 1 (XBP1), which results in the expression of 
transcription factor XBP1s. This factor translocates to the nucleus and upregulates its target 
genes responsible for the ER-associated degradation, mitigation of protein entry into ER, 
upregulation of folding enzymes and chaperones and synthesis of phospholipids for ER 
expansion [79]. 
Stimulation of ATF6 enhances expression of foldases, chaperones and ER-associated 
degradation contributing to the cell adaptation [90]. 
I.2.5.2.4. Apoptotic pathways in chronic or severe ER stress.  
Apoptosis, or programmed cell death, is a type of cell death with a characteristic phenotype. It 
is an essential tool of the organism, used to eliminate damaged or unwanted cells, and it plays 
a crucial role in embryogenesis, hematopoiesis, the proper functioning of the immune system, 
cancerogenesis, etc. Two major pathways control apoptosis: the extrinsic, responding to 
extracellular stimuli, and the intrinsic, responding to intracellular insults like DNA damage 
and major metabolic changes. The extrinsic pathway is triggered by the activation of the cell 
surface death receptor (Fas receptor) when it binds with the death ligand (Fas ligand). This 
complex recruits and activates different caspases, mainly caspase-8, and initiates a caspase 
cascade. The intrinsic pathway is controlled by the balance of proapoptotic and antiapoptotic 
proteins. When the balance moves towards proapoptotic proteins, mitochondrial apoptosis-
induced channel (MAC) formation occurs. Mitochondrial content pours into the cytosol, 
releasing cytochrome c. The latter forms an apoptosome together with Apaf-1 and procaspase-
9. Activated caspase-9 in turn activates caspase-3, which goes to the nucleolus and leads to 
DNA degradation and fragmentation [91], making a final curtain call in the drama of apoptotic 
cell death.  
As mentioned above, when ER stress exceeds a certain threshold, the UPR works on the 
elimination of damaged cells. Adaptive and apoptotic pathways of the UPR sometimes overlap 
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and involve the same signaling molecules. Activated ATF6 as well as activated ATF4, which 
results from PERK pathway stimulation, can upregulate expression of C/EBP homology 
protein (CHOP), which in turn downregulates the expression of antiapoptotic mitochondrial 
proteins of the Bcl-2 family [83, 92]. Upregulation and activation of pro-apototic proteins by 
CHOP and ATF4 have been also observed in previous studies. Bax and Bak are the main 
proapoptotic proteins. Bax, being a cytosolic protein, upon receiving appropriate signals 
undergoes a conformational shift (homo-oligomerization) and translocates to the 
mitochondrial membrane [93, 94]. Bak, initially located on the mitochondria, is oligomerized 
and becomes active. Both active proteins participate in MAC formation [95, 96]. 
Conformational changes of the Bax protein not only induce mitochondrial opening but also 
result in Ca2+ release from the ER lumen [95]. This Ca2+ excess activates calpain in the 
cytosol, which converts ER-localized procaspase-12 to caspase-12 [97]. The caspase 12 
apoptotic pathway is independent from cytochrome c and skips apoptosome formation. 
Activated caspase-12 directly cleaves pro-caspase-9, and activated caspase-9 then activates 
caspase-3 [98, 99]. 
I.2.5.2.5. Caspase-12 protein.  
Caspase-12 is an enzyme which belongs to the caspase family and was first cloned in mice in 
1997 [100]. It is located on the cytoplasmic site of ER in the form of pro-caspase 12 [101, 
102]. Human orthologue was identified and cloned recently [103]. Human caspase-12 have 
nine splice variants, which in most cases contain premature stop-codon and catalytic box 
mutation [103]. A sequencing analysis of more than 1,100 genomic DNA samples from people 
of distinct ethnic backgrounds was carried out with the aim of identifying single nucleotide 
polymorphism (SNP) for the human gene. This study has shown that for most samples DNA  
was mutated and had premature stop-codon TGA at the position 629-631 or TAA at the 
position 761-763 (see Figure 15). Much less frequent, a CGA variant resulting in full-length 
caspase-12 was identified in some samples. All these samples belonged to people of African 
descent. This variant of full-length Casp12 was not found in Caucasian or Asian samples 
tested [104]. Fisher et al. also demonstrated that all human splice variants had the loss-of 
function mutation within the SHG-box, which prohibits full-length human caspase-12 from 
acting catalytically. 
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Figure 15. Structural organization of murine caspase-12 and human pseudo-caspase-12 
and their phylogenic relationship to other caspases.  Premature stop-codon and catalytic 
box mutation of human variant presented as well. Source [105]. 
Most studies concentrated on the role of caspase-12 in ER-stress-induced apoptosis were done 
on murine caspase-12 [105-107]. In the study by Nakagawa et al. [101]cells from caspase-12-
deficient mice were resistant to inducers of ER stress, suggesting that caspase-12 has a 
significant role in ER stress-induced apoptosis [101]. A subsequent study by Morishama et al. 
[98] elucidated upon some of the mechanisms of the caspase-12 involved apoptotic pathway. 
Under the condition of ER stress, upregulation of pro-caspase-12 was observed [99]. Pro-
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caspase-12 is activated by calpain-calcium dependent non-lysosomal cysteine protease and 
caspase-7 [99, 108]. Furthermore, auto-activation by active caspase-12 is possible [98]. Active 
caspase-12 launches mitochondrial independent apoptosis by specific cleavage and activation 
of procaspase-9, which in turn catalyzes the cleavage of procaspase-3 [98]. However, 
functional studies done by Saleh et al. [104] on full-length human caspase-12 failed to prove 
its apoptotic activity. In their experiments there was no significant difference in apoptotic 
activity between WBC from human samples with truncated caspase-12 and from human 
samples homo- and heterozygous for full-length caspase-12 in terms of the response to 
different apoptotic stimuli, including ER stressors. This finding could be attributed to catalytic 
box mutation in human full-length caspase-12, but several years later the same study group 
demonstrated that proteolytic activity of rat caspase-12, which is catalytically competent, is 
confined to itself [109]. They studied different substrates, including caspase-9, and none of 
them, apart from the procaspase-12 itself, was cleaved by activated rat caspase-12 even after 
prolong incubation at high concentrations of enzyme. Saleh et al. suggested instead that the 
caspase-12 protein plays an important role in inflammatory and immune response. It was 
observed that in WBC that expressed full-length capspase-12 there was attenuation of cytokins 
production in response to lipopolysaccharide (LPS). These data correlated with the fact that in 
populations with full-length caspase-12 increased frequency of severe sepsis was noticed. This 
findingwas further reinforced by their 2006 study, which showed that mice with defective 
caspase-12 were resistant to peritonitis and septic shock [110]. Another study by a different 
group showed that full-length caspase-12 suppresses inflammatory responses to malaria and 
modulates inflammation in cerebral malaria [111]. It was suggested that individuals with full-
length caspase -12 might be more resistant to cerebral malaria, a very severe form of the 
disease with extremely high mortality and morbidity rates; the highest incidence is in Sun-
Saharan Africa [112]. The authors also hypothesize that these facts can contribute to the 
maintenance of full-length caspase-12 expression in regions endemic for malaria. This very 
attractive theory, however, was not proven by the study of McCall et al., which found no 
association between the caspase-12 genotype and the severity of malaria or mortality rates 
from the disease in children and pregnant women [113]. 
 27 
The study published in 2006 by Shiraishi et al. [114] challenged the theory that the caspase-12 
pathway is the main pathway of ER-stress-induced apoptosis. They demonstrated that in the 
mouse embryonic fibroblasts (MEFs) caspse-12 was cleaved downstream to Afap-1 and 
caspase-3, and neither overexpression nor knock-down of Caspase-12 affected ER-stress-
induced apoptosis in these cells. Contrary to this, Afap-1 deficient MEFs were more resistant 
to ER-stress-inducing reagents, highlighting the importance of the mitochondrial pathway in 
ER-stress-induced apoptosis. 
Another study, which was done later in 2008 by Bian et al. [115], suggested that in human 
retinal pigment epithelial cells (hRPE) even a truncated variant of caspase-12 can play a role 
in the inflammatory and immune response. As a proof they studied mRNA expression of 
truncated caspase-12 under the stimulation with pro-inflammatory agents, like IL-1β, TNF-α 
andLPS. The RT-PCR results showed that the treatment of the hRPE with these agents 
reduced expression of truncated caspase-12 mRNA.  
In conclusion, these controversies around the role of caspase-12, both full-length and 
truncated, urge us to work more on this mysterious protein in order to better understand its 
role. Why have humans lost the full-length variant? Is it an adaptive mechanism? Why do 
certain populations still express full-length variants, and what are the consequences of having 
it? The limited number of studies already completed in this area does not provide clear 
answers to these questions. In spite of some studies showing that human full-length caspase-12 
has no apoptotic activity [104], these data could be challenged by the fact that they were done 
only in WBC, and were not investigated in other cell types. Although mutation in catalytic box 
can explain an absence of caspase-12 activation, further studies are needed to determine 
caspase-12 involvement in ER-stress-induced apoptosis. Another surprising finding is that 
several studies done on human cell lines and human tissue detected full-length pro-caspase-12 
and active caspase-12 by Western Blot (WB) and even caspase-12 activity by activity assay 
[116-118]. 
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I.2.5.2.6. Gentamicin and ER stress.  
Gentamicin can initiate ER stress when accumulated in cytosol mainly by joining calreticulin 
and inhibiting its necessary chaperone activity for correct posttranslational protein folding 
[119]. Another aspect, which is still controversial, is that gentamicin probably interferes with 
proper protein synthesis by altering ribosomal accuracy. This theory sounds reasonable since 
the main mechanisms of gentamicin antibacterial activity is the disregulation of bacterial 
protein synthesis due to binding with a small unit of prokaryotic ribosome. Several studies 
support the theory. Sundin et al. [120] performed their study with rats that were treated with 
very short course of gentamicin (1–3 days) and sacrificed shortly after treatment, before any 
gross morphological changes in cells would be observed. Sundin et al. reported a significant 
reduction in protein synthesis in cortical homogenate, and this reduction reached 50% 
compared to control samples sacrificed on day three of treatment. Reports from Bennett et al., 
1988 [121], and Monteil et al., 1993 [122], also claimed that gentamicin inhibits protein 
synthesis. Buchanan et al., 1987 [123], used Geneticin, another drug from the aminoglycoside 
group and demonstrated that it alters ribosomal accuracy in human fibroblasts. However, 
Recht et al., 1999 [124], reported that aminoglycoside’s binding capacity to the prokaryote 
ribosomal subunit is very specific. Due to structural differences between prokaryotic and 
eukaryotic ribosomes, the affinity of aminoglycoside to the latter is significantly lower, 
requiring a higher dosage of the drug in order  to bind to a mammalian ribosomal subunit. In 
this study inhibitory concentrations of gentamicin for the eukaryotic 16S ribosomal 
ribonucleic acid (rRNA) was 0.23mM, which is 128 times higher than that for the prokaryotic 
rRNA. 
Another property of aminoglycosides could shed some light on this subject. These medications 
have a potential to induce the read-through for stop-condons [125]. As far back as the 1960s it 
was demonstrated that streptomycin can reduce the fidelity of translation. Many years later it 
was also demonstrated that different drugs of the aminoglycoside group are able to bind to the 
decoding site of ribosomal RNA of both prokaryotes and eukaryotes and bring about a 
conformational change that permits codon–anticodon pairing during translation. Overall, these 
drugs can lead to the continuation of translation through the natural stop-codon. The possible 
usage of this property in clinical practice for disease-causing premature stop mutations 
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initiated several new experiments in which the binding of aminoglycosides with mammalian 
ribosomal subunits was extensively studied. However, in spite of success in the animal model 
of myodystrophy [126] and cystic fibrosis [127], clinical trials of gentamicin treatment in 
therapeutic doses failed to show a stable effect on read-though of defective proteins and 
subsequently any clinical improvement [128, 129]. The question of gentamicin interaction 
with mammalian ribosomes in vivo and the effect of gentamicin on protein synthesis therefore 
remains open. 
I.2.5.2.7. Effect of gentamicin on Casp12 expression. 
Few studies were done on calpain-caspase-12 pathway stimulation by gentamicin. In the 2007 
study by Peyrou et al. [130], demonstrated that in the kidney of the ratsrats treated with 
gentamicin at a dose of 160 mg/kg for seven days there wereno changes in the expression and 
activity of calpain i. Increased cleaved caspase-12 production was detected and the caspase-12 
activity assay showed a slight increase in the protein activity, which was, however, not 
statistically significant. Nevertheless, this study has two major limitations which prevented 
authors from making a firm conclusion. First, the sample was small — only four rats were 
treated with gentamicin. Second, the gentamicin dose was quite high. It had been shown in 
previous studies that high doses induce tubular cell necrosis rather than apoptosis [26, 131]. 
Indeed, on the histology section of the kidney from treated rats, massive tubular necrosis was 
detected.  
Research groups working on gentamicin ototoxicity also provide considerable evidence of the 
importance of the calpain-caspase-12 pathway in inner ear apoptosis and hearing impairment 
[132, 133]. 
In conclusion, gentamicin accumulated in PT cells is able to initiate ER stress by inhibiting 
essential chaperones and probably by reducing protein synthesis and its accuracy. In respond 
to ER stress adaptive mechanism, such as UPR is initiated. When the cytosolic concentration 
of the drug exceeds certain level, UPR switches from pro-survival to eliminative mechanism, 
inducing apoptosis of the cell via mitochondrial and probably, via independent capsase-12 
pathway. The role of the caspase-12 pathway in gentamicin-induced PT cells apoptosis and 
nephrotoxicity is still not well understood and requires further investigations. 
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I.2.5.3. Mitochondrial targeting. 
I.2.5.3.1. Direct effect of gentamicin on mitochondria. 
For many years gentamicin-induced nephrotoxicity was believed to be related to lysosomal 
accumulation of the drug and phospholipidosis. However, recent in vitro studies have shown 
that a critical aspect of gentamicin’s tubular cytotoxicity is its cytosolic concentration [32, 
134]. The most dramatic intracellular events occur when the concentration of gentamicin 
inside the lysosomes, the Golgi and ER exceeds the threshold and destabilizes their 
membranes [72, 135]. After being poured out from ruptured lysosomes, cytosolic gentamicin 
affects mitochondria both directly and indirectly and launches an apoptotic pathway.  
In their study with isolated liver mitochondria of the mouse, which were cultured with 
gentamicin, Mather and Rottenberg, 2001 [136], observed that the drug had a direct effect on 
these organelles. The drug was equally potent in permeability transition pore (PTP) induction 
and outer membrane destabilization, and it induced the release of proapoptotic proteins from 
the intermembrane space. However, the exact mechanism of these destabilizations and PTP 
formations is unknown. Furthermore, gentamicin disturbs electronic transport of the 
mitochondrial respiratory chain, which results in ROS generation and oxidative stress [137]. 
I.2.5.3.2. Gentamicin has an indirect effect on mitochondria via Bcl-2 family of proteins. 
An indirect effect of gentamicin on mitochondria is realized via Bcl-2 family proteins. 
Bcl-2 family of proteins. B cell CLL/lymphoma-2 (Bcl-2) and its relatives form the Bcl-2 
family of proteins, which are the main players of the intrinsic apoptotic pathway. Extensive 
involvement of these proteins in many different pathological conditions, like infections, 
cancerogenesis and auto-immune and neurodegenerative diseases has made them a main focus 
of many studies. The interest in this family of proteins has resulted in the discovery of more 
than 20 members of the family and their functions as well as some new anti-cancer agents 
[138-140]. All members of the Bcl-2 family share one or more of the four characteristic 
domains of homology, called the Bcl-2 homology (BH) domains. Each domain has a number: 
BH1, BH2, BH3 and BH4. These BH domains are crucial for proteins’ functioning, since 
deletion of these domains affects apoptosis rates. The number and combination of BH domains 
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differ from protein to protein and probably determine a protein’s function (see Figure 16). 
Some of the Bcl-2 members also contain a transmembrane domain (TM). 
The Bcl-2 family of proteins is functionally divided into antiapoptotic and proapoptotic 
members. The antiapoptotic members include A1, BCL-2, BCL-w, BCL-xL, and MCL-1, and 
they are generally integrated within the outer mitochondrial membrane (OMM). They bind 
directly to proapoptotic proteins and inhibit their activity, and in doing so preserve OMM 
integrity.  
The proapoptotic proteins are subdivided into “effector” and “BH3-only” members. Two 
“cell-killers,” effector proteins Bcl-2 antagonist/killer 1(Bak) and Bcl-2-associated X protein 
(BAX), are the main participants in OMM channel formation and mitochondrial content 
release. 
 
 
Figure 16.The Bcl-2 family members, divided according to their pro- or antiapoptotic 
properties. Source [141] 
The BH3-only proteins include Bad, Bid, Bik, Bim, Bmf, bNIP3, HRK, Noxa and PUMA. 
These proteins can be called “regulators” since they function as sentinels in response to cell 
damage. There is a growing body of evidence that these activated proteins can directly activate 
 32 
proapoptotic and inhibit pro-survival Bcl-2 members [142]. For example, one study showed 
that activated Bad, Bim and Bmf can bind pro-survival Bcl-2 and in doing so inhibit their 
function. Another study demonstrated the interaction of Bid and Bax (see detail below). 
Growth factor deprivation, UV light and viruses seem to be able to activate BH3-only proteins 
in in vitro studies. However, exact role of Bmf in cell survival and apoptosis   remains unclear  
Bax protein. In normal, healthy cells, Bax is a cytosolic monomeric protein which has no 
channel-forming capacity [143]. It contains BH1, BH2 and BH3 domains and a hydrophobic 
membrane anchor—transmembrane domain (TM) but lacks the BH4 domain. The TM is very 
important for proper Bax function since it determines Bax capacity of mitochondrial insertion. 
Deletion of this domain blocks apoptosis induced by Bax [144]. Upon activation Bax 
translocates to mitochondria, undergoes homo-oligomerization and opens the channel on the 
OMM, which is called MAC [93, 145]. Bax oligomerization is required for channel-forming 
activity in liposomes and to trigger cytochrome c release from mitochondria [146]. The 
mechanisms which activate Bax remain unclear. Studies have shown that it could be activated 
by BH3-only proteins [147], one of which is Bid. It was found that the Bid protein mediates a 
crosstalk between extrinsic and intrinsic pathways [148]. After activation of the extrinsic 
pathway, caspase-8 cleaves Bid, which results in t-Bid formation. t-Bid facilitates Bax 
activation, oligomerization and insertion to OMM.  
Gentamicin can increase the intracellular level of Bax [32], probably by decreasing its 
proteosomal degradation [119] .Furthermore, as discussed above, cathepsins, released from 
ruptured lysosomes, can activate Bid, which turns Bax from the peaceful cytosolic protein into 
the cell-killer [73, 74]. 
Bmf protein. Bcl-2-modifying factor (Bmf) is one of the BH3-only proteins. It is able to 
activate apoptosis by binding to its cognate pro-survival Bcl-2 partner and inhibiting it. In a 
healthy cell Bmf is sequestered to myosin V motors by its association with dynein light chain 
2, and in this way it is kept away from the sites where pro-survival proteins reside. In response 
to apoptotic stimuli, which have an impact on the cytoskeleton, Bmf in complex with their 
respective light chains is released into the cytoplasm, where it can inhibit pro-survival proteins 
and induce apoptosis [149]. Studies have shown, for example, that exposure of the cells to UV 
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light can cause the release of this protein from the motor complex [150]. Another stimuli like 
growth factor withdrawal, histone deacetylase (HDAC) inhibitors and TGF-β treatment can 
also induce Bmf cytosolic release [151].Later studies have demonstrated that Bmf is also a 
central mediator of anoikis — apoptosis in response to inappropriate interaction between cells 
and the extracellular matrix (ECM) [152]. In humans, three different isoforms have been 
identified, and only Bmf-I has a role in the apoptotic process. Bmf-II and Bmf-III failed to 
show any apoptotic activity but appeared to regulate the growth and survival of B-cells and 
leukemic cells [153]. 
 
 
Figure 17. Sequence characterization of Bmf-II and Bmf-III. Human bmf gene and 
proposed derivation of three splice variants   [153] 
Currently, there is no data available on Bmf role in gentamicin-induced apoptosis. 
I. 2. 5. 4. Oxidative stress. 
Cytosolic gentamicin not only activates the apoptotic pathway by acting on mitochondria but 
also produces oxidative stress and impairs cell energy status [154, 155]. These changes 
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contribute to gentamicin-induced cell damage and cell death. ROS can cause cell death via 
necrosis, by inhibition of transmembrane sodium flow, or apoptosis, by inhibition of the 
electronic transport chain, ER-stress activation, direct activation of caspases and alteration of 
lipid metabolism [156]. ROS also activates the inflammatory response through nuclear factor 
kB (NFkB) [157]. Overexpression and overproduction of inflammatory cytokins [158], like 
tumor necrosis factor-alpha (TNF-alpha) and iNOS, occur upon the NFkB activation and 
contribute further to cell damang  [159].In 1994 Nakajima et al. [160] reported protective 
effects of free radical scavengers (Superoxide dismutase (SOD) or dimethylthiourea (DMTU)) 
on gentamicin-mediated nephropathy. This study showed that gentamicin-induced oxidative 
stress is mediated by hydroxyl radicals from hydrogen peroxide and by superoxide anions. A 
year later, Yang et al. [161] demonstrated that these free radicals are of mitochondrial origin. 
These findings were emphasized again in 2002 by Basnakian et al. [162]. Recently, 
mechanisms of reactive oxygen species (ROS) generation under gentamicin treatment were 
elucidated in a study with isolated mitochondria. It appeared that gentamicin directly increased 
the production of mitochondrial ROS from the respiratory chain [137]. Treatment with 
gentamicin reduces activity of cell’s antioxidant system. Decreased intracellular levels of 
glutation (GSH) [163, 164], SOD [165] and catalase [23] were detected following the 
commencement of gentamicin treatment. The importance of oxidative stress in drug-mediated 
kidney damage was highlighted by numerous studies that showed the protective effect of 
different kinds of antioxidants against gentamicin nephrotoxicity. Co-treatment of 
experimental animals with ascorbic acid, vitamin E, grape seed extract, SOD and SOD 
mimetic agents, etc. significantly reduced kidney function impairment and tissue damage 
cause by gentamicin treatment [166, 167]. However, there are few in vitro studies which show 
the same effect ofantioxidants. Quiros et al [54], in their recent review of gentamicin tubular 
nephrotoxicity, mentioned only one study, done by Juan et al. in 2007 [155]. Juan et al. 
reported the protective effect of tetramethylpyrazine (TTP), an antioxidant used in Chinese 
herbal medicine, on gentanicin-induced cell death in rat renal NRK-52E cells. Pre-treatment of 
the cells with TTP reduced ROS generation, cytochrome c release and activation of caspases 
and even increased expression of antiapoptotic protein Bcl-Xl and the overall apoptotic level, 
which was detected by TUNEL assay. In vivo experiments in rats confirmed these findings. 
However, because of the numerous pathways of ROS-induced cell death and the fact that they 
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overlap with other lethal pathways stimulated by gentamicin, the exact mechanism of 
antioxidant protection is still not fully understood. It remains unclear where oxidative stress is 
placed in the hierarchy of gentamicin-induced events, whether it is upstream of ER-stress and 
mitochondrial effect, caused by gentamicin, or whether these pathways act in parallel? Does 
the hierarchy of events change depending on gentamicin dosage? Answers to these questions 
can help to determine the best protective agents against the nephrotoxicity of the drug. Several 
studies were completed with other triggers of oxidative and ER-stress; findings regarding their 
hierarchy, however, remain controversial [168, 169]. 
Studies demonstrate that, apart from its tubular effect, gentamicin also has glomerular and 
vascular effects. In the glomerulus gentamicin induces mesangial cell contractions, mesangial 
proliferation and apoptosis [29, 170]. Gentamicin also can directly induce reduction in renal 
blood flow [171] by increasing the production of vasoconstrictors like endothelin-1 [172] and 
arachidonic acid metabolites [173, 174]. Overall, these changes contribute to reduced GFR 
and worsen tubular damage. Glomerular and vascular effects might explain the fact of the 
relative resistance of isolated cultured PT cells to gentamicin toxicity and gentamicin-induced 
cell death. Only high doses of the drug, starting from 1mM and more, cause a mild degree of 
cell death [30, 175, 176]. This finding highlights the complexityof gentamicin toxicity. 
I. 2. 5. 5. Cell Energy status impairment. 
Finally, gentamicin can cause cell energy status impairment both in vitro and in vivo [177]. 
Hsu et al., 2008 [178], reported that gentamicin treatment reduces levels of peroxisome 
proliferators-activated receptor alpha (PPAR-a). One of the functions of PPAR-a is 
maintaining cell energy homeostasis by activating fatty acid oxidation [179]. Activation of 
PPAR-a reduces oxidative stress and apoptosis  in PT cells, caused by gentamicin both in vivo 
and in vitro [178].  
It was shown in many studies that gentamicin inhibits variety of membrane transporters [180], 
including the Na(+)/glucose co-transporter (SGLT1) [181, 182]. Decreased intracellular 
glucose levels leads to a decreased ATP pool, which in turn makes cells prone to necrosis 
[183]. 
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I.3. Rational for present study. 
In our laboratory Dr. Chan’s team demonstrated that in animal models of diabetes and 
hypertension overexpression of catalase in RPTs can prevent tubular damage and tubular 
apoptosis induced by hyperglycemia and RAS activation [184-187]. 
Catalase is an enzyme which is found in almost every living organism. It converts hydrogen 
peroxide to oxygen and water and plays an important role in protecting cells from oxidative 
damage. In mammals catalase is expressed unevenly in different organs and bodily fluids, 
being especially abundant in the liver, blood and kidneys [188, 189] . 
In the kidney, catalase is localized in the cytoplasmof the proximal tubule cells and was not 
detected in the glomeruli, distal tubules, loop of Henle, or collecting ducts [190]. 
Transgenic (Tg) mice (C57Bl/6 background) overexpressing rat CAT (rCAT) in RPTCs were 
created in Dr.Chan’s laboratory (J.S.D.C.) [185] (see Figure 18). They produced specific and 
inducible expressions of rCAT in RPTCs using the KAP2-rCAT construct. Male Tg mice 
showed a significant overexpression of CAT in the cytoplasm of their proximal tubules [185]. 
Since oxidative stress plays a role in gentamicin-induced nephrotoxicity and many different 
antioxidants have shown protective effect, we hypothesize that CAT overexpression in the 
RPTs can attenuate gentamicin-mediated tubular damage.  
Acute kidney injury model (AKI) studies have shown that one of the mechanisms of renal cell 
damage is loss of cell polarity and cytoskeleton disruption, which, when severe enough, can 
lead to anoikis-type cell death. These effects were shown for some nephrotoxic agents [191, 
192] and were extensively studied for the model of ischemic AKI [193-196]. There are no 
studies that have been done on the gentamicin effect on cytoskeleton and cell integrity. 
However, it is an interesting question that we would like to pursue. Gentamicin has an effect 
on renal blood flow and impairs cell energy status, which can lead to similar changes as in the 
case of ischemic AKI. 
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Figure 18. Generation of Tg mice. (a) Schematic map of the KAP2rCAT construct. The 
rCAT cDNA fused with HA-tag was inserted into the NotI sites in exon II of human Agt gene. 
The transgene was excised as a SpeI and NdeI fragment for microinjection. (b) Southern blot 
analysis of tail biopsies of founders, F1, F2 and F3 generations of Tg mice. Extracted genomic 
DNA was digested with BamHI and migrated onto 0.8% agarose gel. The positive control (+) 
is composed of 10 pg of rCAT cDNA insert mixed with 10 g of WT BamHI-digested genomic 
DNA. (c) Southern blot of RT-PCR product showing tissue expression of rCAT-HA mRNA in 
male uninduced or induced with testosterone Tg mice. rCAT and actin fragments are 
indicated. Male (line no.; 688) mice were induced with placebos or testosterone for two weeks 
before RNA isolation. L, liver; S, spleen; Lu, lung; H, heart; K, kidney; Br, brain; T, testes. (d) 
Western blot analysis of rCAT expression in mouse RPT extracts of male WT and Tg mice 
(line no.;688). (e) CAT activity in mouse RPT extracts of female Tg mice with or without 
testosterone (Testo) induction and male (M) WT and Tg mice. CAT activity is defined as mol 
of H2O2 consumed/min/mg of tissue protein at 10 mM H2O2 (*P<0.05, ** P<0.01, *** 
P<0.005). 
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Moreover, a recent study by Karasawa et al. [53] identified a new gentamicin-binding protein 
in PT cells. This protein, CLIMP-63, is a cytoskeleton-linking membrane protein which was 
found to be localized in ER, and the authors suggest it plays a role in gentamicin toxicity in PT 
cells. Overall, these data urge us to study this possible new mechanism of gentamicin PT cell 
damage and its contribution to gentamicin nephrotoxicity.  
Recently, our laboratory reported that activation of the Bmf protein plays important role in 
apoptosis in diabetic kidneys [197]. We suggested that gentamicin can activate Bmf proteins 
via ROS generation, which in turn triggers an apoptotic cascade and contributes to cell death. 
Overexpression of Cat should prevent induction of Bmf expression and ameliorate kidney 
injury.  
I.4. Objectives. 
The primary objectives of this study were to determine the role of oxidative stress and other 
molecular pathways in gentamicin-induced renal PTs damage and demonstrate protective 
effect of Cat against gentamicin-induced nephrotoxicity. 
 
I.5. Hypothesis. 
1. CAT-Tg mice are more resistant to gentamicin-induced tubular damage and tubular 
apoptosis compared to WT mice when treated with low doses of the gentamicin and in 
immortalized rat renal proximal tubule cells (iRPTC) in vitro. 
2. Getamicin can induce Bmf expression in RPTs cells and as a consequence triggers anoiks of 
renal epithelial cells. Overexpression of Cat in RPTC can attenuate these effects. 
 
3. Gentamicin can induce Casp12 protein expression and activity. Overexpression of Cat 
might attenuate its overexpression or activity, or both.  
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II. MATERIALS AND METHODS. 
II.1. Animals and Treatments.  
18 to 19 weeks old wild type and Cat-Tg males of C57Bl/6 background were used in the 
study. Before and during treatment, animals were housed in a central facility ar CRCHUM, 
submitted to a 12-hour light-dark cycle, provided with standard mouse chow and water ad 
libitum. Animal care and all procedures were approved by the CHUM animal committee.  
Table 1. Experimental animal groups 
Group Mice Gentamicin dose (mg/kg) 
Duration of 
treatment 
(days) 
Euthanasia 
(hours or 
days after 
last 
injection) 
Number of 
mice 
1 WT 32 5 10 days 2 
2 WT 20 5 10 days 8 
3 WT 10 5 10 days 2 
4 Cat-Tg 20 5 10 days 7 
5 WT 20 5 24h 6 
6 Cat-Tg 20 5 24h 6 
7 WT Normal saline 5 24h 5 
8 WT Normal saline 5 10 days 7 
9 Cat-Tg 
Normal 
saline 5 24h 5 
10 Cat-Tg 
Normal 
saline 5 10days 6 
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Gentamicin was injected by the intraperitoneal route after appropriate dilution in 0.9% NaCl in 
order to have a maximum delivered volume of 0.2 ml  per injection (the actual volume 
injected into each mouse was adjusted according to the body weight, which was recorded 
immediately before each drug administration). For control animals, only 0.9% NaCl was 
administered. Animals were sacrificed 24 hours or 10 days after last injections, depending on 
the experimental group. Twenty-four hours before euthanasia the animals were placed 
individually in metabolic cages to collect urine samples. Body weight was measured. Animals 
were sacrificed using intraperitoneal injections of Somnatol, and a laparotomy was done. Both 
kidneys were removed, decapsulated and then weighed together. After longitudinal bisection 
of the left kidney, one half was placed in formaldehyde 4,2% for fixation, then embedded with 
paraffin and processed to paraffin sections; another half was frozen in dry ice and then cut into 
frozen sections. The right kidneys were used for isolation of renal proximal tubule (RPT) by 
the Percoll gradient method [198]. 
II.2. Cell lines and cell culture. 
IRPTC (cell line 93-p-2–1) from passage 12-13 were used. This cell line was obtained from 
Dr. Ingelfinger’s laboratory. Briefly, primary PT cells were isolated from male Wistar rats (4–
5 weeks old) using the Percoll gradient method and were then cultured on collagen-coated T-
75 flasks in Dulbecco’s modified Eagle’s medium containing 5% fetal calf serum. Then cells 
were transfected with origin-defective SV40 DNA mutant 6-1 in pMK 16. Survived cells were 
picked-up and subcultured. These subcultures were then expanded into cell lines. One cell 
line, designed 93-p-2-1, used for the present study, has been characterized and appears stable 
up to 50 passages [199]. Rat PTC in primary culture displayed strong activity for alkaline 
phosphatase, a brush-border marker enzyme for PTC. Cells of the line 93-p-2-1 had 
characteristic markers of proximal tubule cells such as carbonic anhydrase, ecto-ATPase, 
GLUT-2, etc., components of the RAS system (see Table 2) [199] and the presence of 
membrane-bound megalin [200].These described features make the iRPTC cell line a perfect 
model for studying gentamicin nephrotoxicity in vitro.  
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Dulbecco’s modified Eagle medium (DMEM) ph 7.45, containing 4 mM L-glutamine, 4500 
mg/L glucose, 1 mM sodium pyruvate, 1500 mg/L sodium bicarbonate and  supplemented 
with 5% (v/v) fetal bovine serum (FBS), 0.01 mM nonessential amino acids, 100 U/ml of 
penicillin, and 100 μg/ml of streptomycin was used as a culture medium. Frozen cells from 
passage 11 were quickly (< 1 minute) thawed in a 37°C water bath. The vial was then 
transferred into a laminar flow hood. Thawed cells from the vial were transferred under 
aseptic conditions to the centrifuge tube. Pre-warmed DMEM was added again under aseptic 
conditions into the tube. Cell suspension was centrifuged at approximately 200 × g for five 
minutes. After centrifugation the tube was checked for the presence of a sedimentary pellet 
and clarity of the supernatant. 
Table 2. Proximal tubule markers found in iRPTCs line 93-p-2-1 
The amount of immunostaining was judged on a qualitative scale as follows: ±, trace staining; 
+, slight staining; ++, strong staining in 90%–95% of cells; +++, very strong staining in 90%–
95% of cells. Source  [199] 
Proximal tubule marker  Immunostaining 
 GLUT-2 (glucose transporter-2)  ++ 
 SGLT-2 (sodium-linked glucose transporter) ++ 
 Ecto-ATPase ++ 
 Carbonic anhydrase +++ 
 Alkaline phosphatase ++ 
 gp330 (megalin) +++ 
 Aquaporin-CHIP +++ 
 Na-K-ATPase +++ (Baso-lateral)
 RAS (renin-ngiotensin system) components  
 Renin  + 
 Angiotensinogen ++ 
 ACE (angiotensin converting enzyme) ++ 
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Then, supernatant was carefully decanted under the hood. Cells were resuspended in a culture 
medium, seeded at a density of 104 cells/cm2 on Cell+ Tissue Culture Plates 100x20mm 
(SARSTEDT; 83.1802.003) and kept at 37°C in a humidified atmosphere with 95% air–5% 
CO2.  
Cells were allowed to grow to 90% confluence. Then, trypsin 0,05% at the temperature of 
37°C  was used to detach the cells from the dish. The cells were subsequently centrifuged, 
resuspended in the culture medium and subcultured in Cell+ 6-well tissue culture plates 
(SARSTEDT; 83.1839.300). For the experiments, cells at 80% confluence were used. On the 
preceding day, cells were synchronized by replacing the culture medium with serum-free 
DMEM for 24 hours. After that, cells were divided in experimental groups, pre-incubated in 5 
mmol/L glucose DMEM containing 1% depleted FBS for 30 minutes and then treated 
withgentamicin, catalase or both. 
II.3. In vitro experimental groups. 
Cells were divided into treatment groups. Designated groups were treated with gentamicin at 
concentrations of 1.5 mg/ml and 2 mg/ml in the presence or absence of CAT, 300U/ml 
(Sigma-Aldrich Canada Ltd., Oakville, ON,). One group was treated with CAT 300U/ml only. 
The cells were cultured for an additional 24 hours at 37°C in a humidified atmosphere with 
95% air–5% CO2 For the control group, cells were maintained in 1% depleted FBS 5 mmol/L 
glucose DMEM.. After 24 hours the cells were harvested and analyzed by different methods. 
At least three independent experiments in each group were analyzed. 
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Table 3. Cell culture materials and drugs. 
Product Company name 
Normal glucose (5 mmol/L), Dulbecco’s 
Modified Eagle’s Medium (DMEM) 
Gibco® Life Technologies 
100× penicillin/streptomycin  Gibco® Life Technologies 
Fetal bovine serum (FBS) and depleted  
FBS 
Gibco® Life Technologies 
0.05% Trypsin-EDTA Gibco® Life Technologies 
0.1 % MEM NEAA Gibco® Life Technologies 
Gentamicin 10mg/ml Sigma-Aldrich Canada Ltd. 
Catalase  Sigma-Aldrich Canada Ltd. 
II.4. Immunohistochemistry. 
Immunohistochemical staining for Bmf and Bax was performed by the standard avidin-biotin-
peroxidase complex method (ABC Staining System, Santa Cruz Biotechnology, Inc.). 
Formaldehyde-fixed paraffin-embedded mouse kidney sections were dewaxed by baking at 
60° in the oven for 1 hour and then placing in four changes of 100% xylene 5 minutes each. 
Then, sections were hydrated in 3 changes of 100% ethanol for 5 minutes each, 95% and 80% 
ethanol for 5 minute each and rinsed in distilled water. Peroxidase blocking was done using 
0,3% of H2O2 in methanol for 10 min, then slides were washed 2 X 5 minutes with PBS. 
Antigen retrieval was done with a citrate buffer. The buffer was brought to a boil in a 
microwave. The slides then were immersed into the hot buffer and were incubated at a 
subboiling temperature for 5 minutes before being allowed to cool down for 20 minutes at 
room temperature. Next, an IHC pen (Liquid Blocker Super PAP Pen) was used to draw a 
circle around the section in order to ensure an equal covering and save reagents; then, sections 
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were covered with normal blocking serum for 30 minutes according to primary antibody type. 
After blocking, the primary antibody was applied in dilutions of 1:100 or 1:200, and the slides 
were left at 4°C overnight. The next day, the slides were removed from 4°C to room 
temperature and left for 30 minutes to warm up. PBS washing 3 X 5 minutes each was done 
and a secondary antibody at a 1:200 dilution was applied for one hour. An avidin-biotin (AB) 
mixture was prepared and incubated at room temperature for 30 minutes. Upon completion of 
the secondary antibody incubation, the slides were washed in PBS and incubated with the AB 
mixture for another 30 minutes. The slides were then washed again in PBS, and a chromogen 
substrate solution DAB-Peroxidase was prepared. Incubation time for DAB-Peroxidase was 
variable depending on the antibody but never exceeded 10 minutes. Following the distilled 
water wash, the slides were counterstained with hematoxylin for 2 seconds and rinsed in 
running tap water for 5 minutes. Slides then were dehydrated through 70%–100% ethanol, 
cleared in 100% xylene and coverslipped with a mounting medium. Staining was analyzed 
under the microscope using the ImageQ programme.  
Table 4. Solutions and buffers used in IHC. 
Solution/Buffer Composition 
Citrate buffer 10mM Sodium citrate, pH6.0 (adjusted with citric acid) 
Peroxidase blocking 
solution 
1 part of 30% H2O2 in 9 parts of 100% methanol 
Normal blocking serum 
dilution 
15µl of normal serum for 1ml PBS 
Primary antibody 
dilution buffer 
15µl of normal serum for 1ml PBS 
Secondary antibody 
dilution buffer 
25µl of normal serum for 500µl PBS 
AB-mixture 10µl of avidin (A), 10µl of biotinylated HRP (B), 500µl 
of PBS 
DAB-mixture 1,6 mL DDW, 5 drops of 10X Substrate buffer, 2 drops 
of 50X DAB and 2 drops of 50X Peroxidase substrate  
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Table 5. Antibodies and sera used in IHC. 
Antibody Host Company 
Anti-Bax B-9 (sc-7480) Mouse Santa-Cruz 
Anti-Bmf N-19 (sc-20181) Goat Santa-Cruz 
Donkey blocking serum* Donkey Santa-Cruz 
Goat blocking serum** Goat Santa-Cruz 
Biotinylated Second anti-mouse antibody** Goat Santa-Cruz 
Biotinylated Second anti-goat antibody* Donkey Santa-Cruz 
* Part of goat ABC staining system (sc-2023)  
**Part of mouse ABC staining system (sc-2017) 
 
II.5. Detection of apoptosis. 
 For in vitro studies two methods of apoptosis detection were used: morphological study of 
stained nuclei and caspase-3 activity assay. 
II.5.1. DAPI nuclear staining.  
Apoptotic cells were enumerated after they were stained with 4’,6-diamidino-2-phenylindole 
(DAPI) to reveal the characteristic nuclear changes of apoptosis (condensation and 
fragmentation of the nuclear material and apoptotic body formation).  
Working solutions: 
1) Washing solution: PBS pH 7.4 
2) Fixing solution: 4% paraformaldehyde solution in PBS, pH 6.8. The solution was prepared 
under the hood on a hot plate with a magnetic stirrer; NaOH 1M was used to facilitate dilution. 
Diluted HCL was used for pH adjustment.  
3) Staining solution: DAPI stock solution diluted in PBS pH 7.4 at a concentration of 300 nM. 
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For this experiment cells were cultured in chamber slides (Lab-Tek II Chamber Slide system 
4-well Glass Slide, VWR), divided into several treatment groups, synchronized and treated as 
described above. Twenty four hours after treatment cells were gently washed with warm PBS 
and fixed with 4% paraformaldehyde solution for 15 minutes. The fixing solution was 
decanted and cells were washed with PBS. Next, cells were incubated with DAPI staining 
solution for five minutes in the dark. Afterward, cells were rinsed with PBS, the polystyrene 
removable chamber was removed from the slide, and slide was mounted with 40% glycerol in 
the PBS mixture and then covered with coverslip. Staining was analyzed under the microscope 
(Nikon, Eclipse TE 2000-5) using a UV filter. 
II.5.2. Caspase-3 activity assay. 
Caspase-3 activity was measured with a caspase-3 activity assay kit, purchased from BD 
Biosciences Pharmingen (Mississauga, ON, Canada). This kit uses caspase-3 fluorogenic 
substrate (Ac-DEVD-AMC) to measure caspase-3 activity. The procedure was done according 
to the company’s protocol. Briefly, treated cells were washed with PBS, trypsinized and 
pelleted by centrifugation. The pellets were then resuspended in the cold cell lysis buffer, 
which comes with the kit, in order to achieve a suspension of approximately 106 cells/ml 
before being left on the ice for 30 minutes. Reaction was done on 96-well reading plate. For 
each reaction, 5 µl of reconstituted caspase-3 substrate was added to the well containing 0.2 
ml of HEPES buffer. Samples were added at the volume of 50 µl per well. Cell lysate from the 
cells treated with staurosporin 1 mM for 24 hours were used for positive control. Two negative 
controls were also used. The first was a reaction mixture without added cell lysate. For the 
second negative control, a caspase-3 inhibitor was added to the reaction mixture containing 
HEPES buffer, caspase-3 substrate and cell lysate from the cells treated with staurosporin. 
Reaction mixtures were incubated for one hour at 37°C in the dark. Plate reading was done 
using a plate reader with an excitation wavelength of 380 nm and an emission wavelength 
range of 460 nm. Results were normalized with protein concentration, which was measured 
using the Bradfort method. Cell lysates from staurosporin-treated cells yielded a considerable 
emission as compared to both negative controls. 
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II.5.3. Immunohistochemical demonstration of apoptosis.  
Apoptotic cells in the mouse kidney sections were detected by TdT-mediated extension of 
3’OH ends of fragmented DNA using fluorescein-labeled dUTP as a precursor (TUNEL). 
Reagents were purchased as a commercially available kit (TUNEL kit; Roche Diagnostics). 
The procedure was carried out on formaldehyde-fixed paraffin-embedded mouse kidney 
sections in accordance with the supplier’s recommendations. To put it briefly, sections were 
dewaxed, rehydrated and pretreated with Permeabilisation solution (0,1% Titon X-100, 0,1% 
sodium citrate, freshly prepared) for eight minutes at room temperature. After being rinsed, the 
sections were incubated for 60 minutes in a TUNEL reaction mixture (5 µl of TUNEL 
Enzyme to 45 µl of TUNEL Label). At the end of the incubation, the sections were rinsed, 
stained with DAPI, mounted and then analyzed under fluorescent light. Other times, we 
proceeded to the next steps in order to analyze staining with light microscopy. After labeling, 
the sections were incubated with an anti-fluorescein antibody, TUNEL AP, at 37°C for 30 
minutes. Sections were washed and incubated with NBT/BTIP solution for 10 minutes in the 
dark at room temperature. Then, sections were dehydrated, mounted and sealed. Positive and 
negative controls were used for quality assurance. For the positive control, sections were 
pretreated with DNase for 10 minutes before labeling, and we clearly observed the appearance 
of a large number of immunostained nuclei. For the negative control, sections were treated 
with TUNEL Label only; no labeling was seen in this case. 
The percentage of apoptotic RPTCs (TUNEL kit; Roche Diagnostics) was estimated semi- 
quantitatively as described by Kumar et al.. [201] 
II.6.Western blot. 
II.6.1. Protein extraction.  
After 24 hours of treatment, plates with cultured iRPTCs were placed on ice and washed 
gently two times with ice-cold PBS. 100 μL of a RIPA lysis buffer containing protease 
inhibitor (Complete Protease Inhibitor Cocktail Tablets, Roch) were then added per Petri 
plate. Cells were scraped with a cell scraper and transferred to pre-chilled labeled Eppendorf 
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tubes kept on ice and then vortexed. Two sonications of 10 seconds each were performed and 
the samples were centrifuged at 12,000 rpm at 4°C for 15 minutes. The supernatant was 
transferred to new pre-chilled eppendorf tubes, which  were labeled and kept at -80°C until 
next use. 
Table 6. RIPA buffer ingredients with concentrations. (Stored at 4°C). 
Ingredient  Concentration , volume Reference  
Tris-HCL, pH 7.4 50mM  (25 ml of 1M) ACP S-2838  
Triton X-100 1%  (5 ml) Sigma T-8787  
Na deoxycholate 
(C24H39NaO4)  
0.5 %  (2.5 g) Sigma D6750  
SDS  0.1%  (0.5 g)  Invitrogen 15525-017  
NaCl 150 mM  (15 ml of 5 M) Invitrogen 15504-020  
EDTA pH 8.0 2 mM (2 ml of 0.5 M)  
DDW Ad 500 ml  
II. 6.2. Protein quantification.  
Protein concentration in the samples was measured using the Lowry method, the principle of 
which lies in the reactivity of the peptide nitrogens with the copper ions under alkaline 
conditions and the subsequent reduction of the Folin-Ciocalteay 
phosphomolybdicphosphotungstic acid to heteropolymolybdenum blue by the copper-
catalyzed oxidation of aromatic acids. The end product has a blue color. The amount of the 
protein in the sample is then estimated by reading the absorbance (at 750 nm) of the end 
product against a standard curve of standard protein solutions, which in our case was Bovine 
serum albumin (BSA) solutions in the RIPA buffer from 1,25 mg/ml to 10 mg/ml. 
 49 
 
II. 6.3. Electrophoretic migration of protein samples. 
II.6.3.1. Sample preparation.  
After protein quantification, the samples were prepared for electrophoresis by diluting each 
one to the same final concentration (30–60 μg protein/mL) with 5X Protein loading dye and 
water to obtain a final volume of 2025 μL for each sample. Each sample had an equal volume 
to favour even migration on the gel. The samples were then heated at 90°C for 5minutes.  
Table 7. 5X protein loading dye. 
Component  Concentration  Reference  
1.5 M Tris HCl  300 mM  Invitrogen 15504-020  
Glycerol  50%  Sigma G6279  
β-mercaptoethanol  5%  Gibco 21985-023  
SDS  10%  Invitrogen 15525-017  
1% Bromophenol Blue  0.050%  Sigma B-5525  
 pH 6.2 (adjusted) 
II.6.3.2. Preparation of SDS polyacrylamide gels.  
A 10% running gel was prepared and cast on BioRad glass supports with 0.5 mL isobutanol 
poured gently on top of each gel. After polymerization of the running gel, a 4% acrylamide 
stacking gel was cast on top of the running gel and a protein comb of 10 or 15 wells was 
placed into the gel. The gels had a final width of 1.0 mm.  
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 Table 8. Solution used in SDS-PAGE preparation. 
Solution  Volume 
1.5 M Tris pH 8.8  Runnng gel  
0.5 M Tris pH 6.8  Stacking gel  
Acrylamide stock (29% acrylamide, 
1% bisacrylamide)  
Invitrogen 15512-023  
SDS 10%  Invitrogen 15525-017  
APS (0.1 g/mL)*  Sigma A3678  
TEMED  Sigma T-8133  
 
After polymerization the gels were transferred and cast on an electrophoresis machine (Bio-
Rad Mini Protean Tetra Cell). The chamber was filled with running buffer (192 mM glycine, 
25 mM Tris, 1% SDS, pH 8.3). Samples were loaded in the wells. Standard molecular weight 
marker (Bio-Rad) was loaded as well .The electrophoresis chamber was connected to a power 
source. The electrophoresis was carried out at 80V for 30 minutes and then at 100V for 1.5-3 
hours until the protein ladder band become well separated. 
II.6.4. Fixing of the protein on PVDF membrane. 
A transfer buffer was freshly prepared containing 192 mM glycine, 25 mM Tris and 20% 
methanol, and was kept cold (4°C) until use. Upon completion of electrophoresis, a transfer 
“sandwich” was prepared. Pre-cut pieces of sponge and Whatman filter blotting paper were 
soaked in transfer buffer. The PVDF membrane (Immuno-blot PVDF membrane, Bio-Rad) 
was activated in 100% methanol for 5 minutes and then washed in the transfer buffer. A 
blotting sandwich was formed in the following order: sponge; two pieces of blotting paper and 
gel containing proteins, placed on the anode plate of the transfer cassette;  activated PVDF 
membrane carefully placed on top of the gel; another two pieces of blotting paper; and sponge. 
The sandwich was then covered with a cathode plate of transfer cassette. The bubbles were 
squeezed out and cassettes were cast on the transfer tank. The transfer tank was placed at 4°C 
and the transfer was carried out at 35 V overnight.  
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II.6.5. Incubation with antibodies and visualization of results.  
Upon completion of the transfer, the membranes were stained with Ponceau red (aqueous 
solution containing 0.2% w/v Ponceau red and 0.75% w/v trichloroacetic acid) for one minute 
and then rinsed in order to visualize the proteins and ensure the quality of the transfer. The 
membranes were then washed with TBS-T (25 mM tris, 150 mM NaCl, pH 7.4+ 0.1% Tween-
20). The membranes were incubated in blocking solution (5% fat-free milk in TBS-T) for one 
hour at room temperature to prevent unspecific antibody binding.  
After blocking, the membranes were washed 3 X 5 minutes with TBS-T and incubated 
overnight with a primary antibody at a 1:1000 dilution (the antibody was diluted in TBS-T 
with 2% BSA) and incubated overnight at 4°C on a shaker. The membranes were then washed 
3 X 5 minutes each wash in TBS-T and incubated with appropriate dilutions of horseradish 
peroxidase-linked secondary antibody at a 1:2000 dilution (the antibody was again diluted in 
TBS-T with 2% BSA).  
A Bio-Rad Detection kit and autoradiography films were used to visualize the results. Films 
were developed on a Kodak X-Omat 2000A processor.                  .                                                                     
II.7. ROS detection. 
ROS detection was performed with dihydroethidium (DHE) staining. DHE is a hydrophobic 
uncharged compound that is able to cross intracellular membranes. Upon oxidation DHE 
becomes positively charged, accumulates in cells by intercalating into DNA and gives bright 
red fluorescence [202]. 
Frozen kidney sections were place in PBS at room temperature and washed 2X with five 
minutes each. AnIHC pen was used to draw a circle around the sections. Dehydroethidium 
(DHE, Sigma-Aldrich Canada Ltd.) at the dilution of 1:1000 in PBS was applied and slides 
were incubated for 30 minutes at 37°C in the dark. The slides were then washed in PBS 2X 
with 5 minutes each and incubated in DAPI solutions for another five minutes. After the PBS 
wash, the slides were mounted with 40% glycerol in PBS medium and coversliped. Analysis 
of the experiment was done immediately under microscope (Nikon, Eclipse TE 2000-5) using 
a green filter for DHE and a UV filter for DAPI staining. 
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II.8. Caspase-12 activity detection. 
For detection of caspase-12 activity in isolated RPTs of the experimental animals, we used the 
Caspase-12 Fluorometric Assay Kit (BioVision Incorporated, Cat# K-139-25). Caspase-12 
catalytic activity was measured by using a continuous fluorometric assay based on the 
proteolytic cleavage of a substrate, ATAD-AFC (AFC: 7-amino-4-trifluoromethyl coumarin). 
ATAD-AFC itself emits blue light (λmax = 400 nm). Upon cleavage by caspase-12, free AFC 
emits a yellow-green fluorescence (λmax = 505 nm), which can be quantified using a 
fluorometer or a fluorescence microtiter plate reader (from the company’s protocol). 
Cells were divided into experimental groups and treated as described above. Treated cells 
were washed with PBS, trypsinized and pelleted by centrifugation. Pellets were then 
resuspended in the cold cell lysis buffer, which comes with the kit, in order to achieve a 
suspension of approximately 106 cell/ml, and were then kept on the ice for 30 minutes. Then 
50 µl of cell lysate from each sample was transferred to the 96-well reading plate. Next, 50 µl 
of 2X Reactin Buffer, containing 10 mM of DTT, was added to each well. For each reaction, 5 
µl of the ATAD-AFC substrate was added. Reaction mixture without added cell lysate was 
used as a negative control. Reaction mixtures were incubated for two hours at 37°C in the 
dark. Plate reading was done using a plate reader with an excitation wavelength of 380 nm and 
an emission wavelength range of 460 nm. Results were normalized with protein concentration 
which was measured using the Bradfort method.  
II.9. Statistical analysis. 
All data were processed using Prism 5 software (GraphPad Software, California, USA). One-way 
ANOVA with Holm-Šidàk multiple comparisons was performed. Grouped data were analyzed 
using two-way ANOVA. When significance was obtained, groups were further compared using 
unpaired student t-test Results are presented as the mean ± SEM. Results were considered 
significant when p < 0.05. 
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III. Results. 
 III.1. Gentamicin induces dose-dependent kidney damage in wild 
type C57Bl/6 mice. 
Most studies in the field of gentamicin nephrotoxicity using animal models have been 
performed with rats and less frequently mice of different genetic backgrounds. In the mini-
review of Ali et al., 2011[203], the most common doses of gentamicin used in animal studies 
was 80–100 mg/kg/day. These are very high doses compared to those used in humans, which 
almost never exceed 10 mg/kg/day. However, it was shown that even low doses, like 1020 
mg/kg are able to induce tubular apoptosis in rats [25] and morphological kidney changes in 
C57Bl/6 mice [204]. It should be mentioned that, in the last case, mouse kidneys were 
compromised with intraperitoneal injections of 10 mg/kg L-NAME (NG-nitro-L-arginine 
methyl-ester) and 10 mg/kg Indomethacin 20 minutes before gentamicin injections to ensure 
significant nephrotoxicity.  
The aim of our research was to study tubular apoptosis that occurs with low doses of 
gentamicin treatment, because high gentamicin doses more likely induce tubular necrosis. 
Recent strategies for gentamicin usage in clinical practice are to make gentamicin courses as 
short as possible and then switch the patient to another acceptable antibiotic [205]. In order to 
make our study approximate more closely this clinical model, we decided to use a short course 
of gentamicin treatment. Since there are limited data on low-dose gentamicin treatment in 
C57Bl/6 mice, we had to test our model first in order to find the optimal dose and duration of 
treatment. The optimal dose and duration of treatment should have been close to therapeutic 
doses used for humans and at the same time should induce obvious tubular apoptosis and 
tubular morphology changes. We have tested three doses simultaneously: 10, 20 and 32 
mg/kg, using 2 to 3 animals per dose. Animals were treated with intraperitoneal injections for 
5 consecutive days and were sacrificed 10 days after the last injection. We observed that 
gentamicin induced dose-dependent kidney damage and tubular apoptosis (see Figures 19, 20). 
There were minimal morphological changes and almost no tubular apoptosis in the kidneys of 
the mice treated with 10 mg/kg of gentamicin. With gentamicin doses of 20 mg/kg there was 
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significant morphology changes and tubular apoptosis, and doses of 32 mg/kg induced severe 
damage and abundant tubular apoptosis. From these studies we were able to conclude that a 
gentamicin dose of 20 mg/kg is the most suitable dose for our study in the C57Bl/6 mouse 
model and five days of treatment is sufficient. We continued our study using this dosage and 
treatment period. 
 
Figure 19. PAS staining of the kidney section (cotrex) of control (A) and Gentamicin-
treated animals (B, C, D). Minimal morphology changes were observed in kidneys of the 
animals treated with 10mg/kg (B), brush-border and basal membrane of PCT were preserved. 
In the kidneys of the animals treated with 20mg/kg (C), significant dilation of PCT was 
observed: there was vacuole degeneration of PCT epithelial cells, nuclear pyknosis (black 
arrows) and loss of brush-boder. The kidneys of the animals treated with 32mg/kg (D) showed 
severe tubular dilation and cytolasmatic vacuoles, karyolitic nuclei (black arrows), detachment 
of the cells and cell debris (red arrows). Original magnification 200X. 
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Figure 20. Apoptotic nuclei detected by TUNEL assay in kidney cortex of control 
animals (A) and gentamicin-treated animals (B, C, D). Almost no apoptotic cells were 
detected in sections of the mice treated with 10 mg/kg (B). There was a significant number of 
apoptotic cells (arrows) in PCT of the mice treated with 20 mg/kg (C), and in the kidney 
sections of the mice treated with 32 mg/kg tubular apoptosis was even more prominent (D). 
Original magnification 200X. 
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Figure 21. Quality control of the TUNEL assay. Negative control (A); Positive control (B); 
Close-up view of apoptotic cells in the renal tubule (C) with DAPI (D) and Merge image (E) 
as a proof of the true nuclear staining. 
 
III.2. Catalase overexpression in mouse PT protects kidney against 
gentamicin - induced kidney damage and tubular apoptosis. 
WT and Cat-Tg mice were treated with the chosen dose of gentamicin for 5 days and were 
sacrificed on day 10 after the last injection. PAS staining and TUNEL assay on paraffin mice 
kidney sections was then performed to assess morphology and tubular apoptosis. We observed 
that in Cat-Tg mouse kidneys there was only slight tubular dilation, almost no vacuole 
dystrophy or tubular apoptosis, which brought us to conclude that catalase overexpression 
almost completely prevents gentamicin-induced morphological changes (Figure 22). 
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Figure 22. PAS staining (A, B) and TUNEL assay (C, D). Representative images of the 
kidney sections of the mice treated with gentamicin 20 mg/kg and sacrificed on day 10 after 
the last injection. There is tubular dilation, vacuole dystrophy of PCT cells and PCT cells 
apoptosis (arrows) in WT mouse kidneys (A, C). There is only slight tubular dilation, almost 
no PCT cell dystrophy and apoptosis in Cat-Tg mouse kidneys (B, D). Original magnification 
200X. 
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Mice sacrificed after the treatment had more damage and tubular apoptosis.  
Apoptosis can be divided into early, intermediate and late stages, each of which having a 
particular and distinguishable morphology. In the early stage, affected cells lose 
mitochondrial membrane potential and translocation of phosphatidylserine (PS), a protein 
normally cytosolic, to the extracellular portion of the cell membrane occurs. However, in the 
early stage the cell and its nucleus can look intact, meaning that special techniques like JC-1 
dye and Annexin V labeling have to be done to detect these early changes. In the mid and late 
stages chromatin condensation, fragmentation of DNA and apoptotic body formation occur. 
Nuclear staining techniques with DAPI and Hoechst are used to visualize nuclear morphology, 
and TUNEL assay detect apoptotic cells by binding and staining blunt ends of double-stranded 
DNA breaks. Apoptotic cells in their late stages have very prominent features and could be 
detected by an experienced pathologist even in routine staining like H&E. 
Apoptotic cells can very quickly lose their connections, get detached and be flushed out of the 
organ. So, when performing apoptotic detection assays the time after the insult needs to be 
considered. We detected a considerable amount of apoptotic cells in treated animals sacrificed 
10 days after gentamicin  treatment (see Figure 23), and we choose this time point based on 
the fact that in clinical practice AKI induced by gentamicin usually occurs on day 7 to 10 of 
treatment. However, we decided to study another time point, 24 hours after 5 days of 
gentamicin treatment, in order to assess early changes induced by gentamicin. 
Interestingly, we detected significant proximal tubular damage and dilation in WT-treated 
animals, as well as detached epithelial cells and casts in the tubular lumen. TUNEL assay 
showed positive stained detached cells in the lumen of PTC. These changes were attenuated 
by overexpression of Cat in PCT cells in gentamicin-treated Cat-Tg mice, as shown in Figures 
24. In order to demonstrate that TUNEL staining of detached cells in tubular lumen is a true 
staining and not an artifact, we stained slides with DAPI. TUNEL positive cells in tubular 
lumen showed positive nuclear staining as well, which confirmed the specificity of TUNEL 
staining in these cells (see Figures 25-26). 
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Figure 23. Representative images of the kidney sections of control WT (A) and Cat-Tg (B) 
mice; WT (C) and Cat-Tg mice treated with gentamicin 20 mg/kg and sacrificed 10 days after 
the last injection. Original magnification 200X.  
A 
D 
C 
B 
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Figure 24. PAS staining (A, B) and TUNEL assay (C, D). Representative images of the 
kidney sections of the mice treated with gentamicin 20 mg/kg and sacrificed 24 hours after 
the last injection. There is severe tubular dilation of PCT, casts and clusters of TUNEL-
positive desquamated cells in tubular lumen (arrows) in WT mouse kidneys (A, C). There was 
less severe tubular dilation and fewer isolated casts (black arrows) and apoptotic cells (red 
arrows) in Cat-Tg mouse kidneys (B, D). Original magnification 200X. 
 
 
D C 
B A 
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Figure 23. TUNEL (left) and DAPI (right) staining. Representative images of the kidney 
sections of control WT (A) and Cat-Tg (B) mice, and WT (C) and Cat-Tg mice treated with 
gentamicin 20 mg/kg and sacrificed 24 hours after the last injection. Original magnification 
200X. 
A 
D 
C 
B 
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Figure 24. TUNEL and DAPI staining of detached cells in tubular lumen. Representative 
images of the kidney sections of WT mice treated with 20 mg/kg of gentamicin and sacrificed 
24 hours after the last injection. 200X (A) and 600X (B) magnifications. 
 
Body and kidney weights of experimental animals were analyzed. Animals were weighed on 
the first, third and last day of treatment and on the day when the animals were sacrificed. For 
the those animals who were sacrificed 10 days after treatment we continued to measure body 
weight every other day after the termination of the treatment and one more time right before 
euthanasia. Significant weight reduction was noted in WT-treated animals but was much less 
prominent in Cat-Tg-treated mice (see Figure 27). 
 
A B
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Figure 25.  Mice body weight dynamics. A. Mice treated with gentamicin 20 mg/kg and 
sacrificed 24 hours after injections. (Legend: A — WT control; B — Cat-Tg control; C — WT 
treatment group; D — Cat-Tg treatment group) B. Mice treated with gentamicin 20 mg/kg and 
sacrificed 10 days after last injections. N of the animals per group — see Table 1.   
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Kidney weight was measured right after kidneys were removed from the body and cleaned 
from the adventitial tissue. Kidney weight was adjusted to body weight (see Figure 28).  
 
Figure 26. Kidney weight / body weight ratio (KW/BW). Legend A — WT control; B — 
Cat-Tg control; C  WT and D — Cat-Tg mice treated with gentamicin 20 mg/kg and sacrificed 
24hours after the last injection; E — WT and F-Cat-Tg mice treated with gentamicin 20 mg/kg 
and sacrificed 10 days after the last injection. N of the animals per group — see Table 1 
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Urine output was measured in animal groups sacrificed 24hr after injections. Mice were placed 
in metabolic cages for 6 hours on day 0 and again on day 5 of the treatment. Urine output was 
not statistically different between the groups on day 0. However, we observed significant 
decrease in urine output in WT-treated animals on day 5 of the gentamicin treatment (figure 
29). 
 
Figure 27. Urine output measured in animal groups on day 5 of the gentamicin 
treatment. Legend A — WT control; B — Cat-Tg control; C  WT and D — Cat-Tg mice 
treated with gentamicin 20 mg/kg and sacrificed 24hours after the last injection.  
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III.3. Gentamicin induces ROS generation in the kidneys of WT 
mice but Cat overexpression in Cat-Tg mice mitigates ROS 
formation induced by gentamicin. 
In order to better understand the protective mechanism of Cat we tested several pathways 
involved in gentamicin nephrotoxicity. We chose Bax and Bmf proteins to validate the effect 
of Cat on the mitochondrial apoptotic pathwaycaspase-12 protein, as an effector of ER-stress-
induced apoptosis measurement of ROS generation as amarler of oxidative stress. 
DHE-staining was performed on frozen sections in order to estimate ROS generation. It was 
observed that in the kidneys of WT mice treated with gentamicin 20 mg/kg and sacrificed 24 
hours after the last injection there was a significant increase of ROS generation. In the kidneys 
of Cat-Tg mice treated with gentamicin 20 mg/kg and sacrificed 24 hours after the last 
injection there was a slight increase of ROS generation compared to the control, but this 
increase was statistically less compared to WT-treated mice. In contrast, in the kidneys of WT- 
and Cat-Tg-treated mice sacrificed 10 days after the last injection there was no statistically 
significant increase in ROS generation compared to the control. 
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Figure 28. DHE (left) and DAPI (right) staining. Representative images of the kidney 
sections of control (A), WT (B) and Cat-Tg (C) mice treated with gentamicin 20 mg/kg and 
sacrificed 24 hours after last injections. Images of control Cat-Tg kidney sections are not 
presented. Original magnification 200X.  
 
 
 68 
 
 
Figure 29. DHE (left) and DAPI (right) staining. Representative images of the kidney 
section of control (A), WT (B) and Cat-Tg (C) mice treated with gentamicin 20mg/kg and 
sacrificed 10 days after the last injection. Images of control Cat-Tg kidney sections are not 
presented. Original magnification 200X. 
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Figure 30. Quantification of DHE staining in mouse kidney sections. Control WT (A) and 
Cat-Tg (B); mice treated with 20 mg/kg of gentamicin and sacrificed 24 hours after treatment 
WT (C) and Cat-Tg (D) groups; mice treated with 20 mg/kg of gentamicin and sacrificed 10 
days after treatment WT (E) and Cat-Tg (F) groups. Values are the mean ±SEM, n= 5-d6 for 
each group. *P < 0.05; *** P < 0.005; N.S., non-significant. 
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III.4. Gentamicin induces Bax and Bmf overexpression in PCT 
cells that persist at least 10 days after termination of the 
treatment. 
Acute kidney injury (AKI), which contributes significantly to morbidity and mortality among 
hospitalized patients, is frequently multifactorial,with ischemia and nephrotoxins being the 
most common causes. Regardless of cause, histologic findings include dilated and flattened 
epithelium, loss of tubular epithelial cells and the presence of Tamm-Horsfall protein (THP)-
rich casts. Frank necrosis is not usually apparent, and apoptotic cells are consistently found in 
both ischemic and nephrotoxic forms of clinical AKI. 
Bmf overexpression was observed in PCT cells in both WT- and Cat-Tg-treated animals; 
however, it was much more prominent in the WT-treated group. Bmf overexpression was still 
significant in the kidneys of treated animals that were sacrificed 10 days after treatment, being, 
again, less abundant in treated Cat-Tg mouse kidneys (see Figure 33).  
 
Bax protein was dramatically increased in RPTs as well as in the distal tubules of treated 
animals, both WT and Cat-Tg. Bax staining was localized mostly in dilated damaged tubules. 
Even though Bax expression was attenuated in Cat-Tg-treated mice, it was still high compared 
to Cat-Tg control animals (see Figure 34). 
Interestingly, in the kidneys of WT-treated animals sacrificed 24 hours after the last injection, 
detached cells, seen in the 
 tubular lumen of dilated and damaged PCT, were also stained positively for Bmf and Bax (see 
Figure 35). 
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Figure 31. Bmf immunohystochemical (IHC) staining and its quantification in kidney 
section from control and gentamicin treated (20 mg/kg) mice, sacrificed at different time 
points. Representative pictures of control WT (A) and Cat-Tg (B) mice and treated animals: 
WT (C) and Cat-Tg (D) sacrificed 24 hours after the last injection; WT (E) and Cat-Tg (F) 
sacrificed 10 days after the last injection. N of analyzed animals per group = 5. Original 
magnification 200X. 
A B 
C D 
E F 
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Figure 32. Bax immunohystochemical (IHC) staining and its quantification in kidney 
section from control and gentamicin treated (20 mg/kg) mice, sacrificed at different time 
points. Representative pictures of control WT (A) and Cat-Tg (B) mice and treated animals: 
WT (C) and Cat-Tg (D) sacrificed 24 hours after the last injection; WT(E) and Cat-Tg (F) 
sacrificed 10 days after the last injection. N of analyzed animals per group = 5. Original 
magnification 200X. 
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Figure 33. Bax (A) and Bmf (B) stained detached cells in the tubular lumen of proximal 
tubules of WT treated mice sacrificed 24h after the last injection. 
III.5. Gentamicin induces Caspase-12 overexpression and activity 
in renal proximal tubules (RPTs) of mice treated with 20 mg/kg of 
gentamicin and sacrificed 24 hours after last injections.  
Caspase-12 overexpression was observed by IHC in RPTs of treated animals. It was 
significantly higher in WT-treated animals compared to Cat-Tg, and it was higher in animals 
sacrificed 24 hoursr after last injections than in animals sacrificed 10 days later (see Figure 
36). 
Caspase-12 activity was measured in isolated RPTs using caspase-12 activity assay. 
Gentamicin induced significant elevation of caspase-12 activity in both WT and Cat-Tg mice. 
There was a slight decrease in caspase-12 activity in RPTs of Cat-Tg mice; however, the 
difference was not statistically significant compared with WT-treated mice (see Figure 37). 
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Figure 34. Casp12 immunohystochemical (IHC) staining and its quantification in kidney 
section from control and gentamicin treated (20mg/kg) mice, sacrificed at different time 
points. Representative pictures of  control WT (A) and Cat-Tg (B) mice and treated animals: 
WT (C) and Cat-Tg (D) sacrificed 24h after last injection; WT(E) and Cat-Tg (F) sacrificed 10 
days after last injection. N of analyzed animals per group=4. Original magnification X200. 
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Figure 35. Casapse -12 activity in RPTs. Values are corrected to lysate protein. Samples 
from 4-5 animals per group were used for this experiment. 
 
III. 6. Gentamicin reduces  viability of cultured iRPTC cells with 
apoptosis being the main mechanism of cell death. Co-treatment 
with Cat improves cell survival and diminishes apoptosis of the 
gentamicin-treated cells.  
We also did in vitro study in rat immortalized RPTCs (iRPTC) cells. As discussed above, 
relatively high doses of gentamicin are required in order to induce apoptosis in vitro. We 
chose the doses of 1.5 and 2.0 mg/ml as used in the study of Servais et al. (2006), who 
reported that these doses induced significant apoptosis in porcine immortalized RPTCs (LLC-
PK1) cells. Co-treatment with Cat was done for another experimental group in order to assess 
the protective effect of Cat in vitro. 
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First, we checked cells viability using Trypan blue and hemocytometer. Gentamicin reduced 
cell viability in dose-dependent manner while co-treatment with Cat improved cell survival 
(see Figure 38). 
 
 
Figure 36. Cell viability of iRPTC cells treated with Gentamicin at 1.5 and 2.0 mg/ml    
alone and with Cat co-treatment. This experiment was done in duplicate and 3 experimental 
situations in each group were analyzed. A slight increase in number of death cells in Cat-only 
treated cells was not statistically significant compared to non-treated cells.  
 
In order to assess predominate cell death type, nuclear staining and caspase-3 activity assay 
were performed. Apoptotic cells with condensed chromatin and apoptotic-bodies were 
observed in gentamicin-treated cells and the number of apoptotic cells increased along with 
the dose of gentamicin. Co-treatment with Cat prevented apoptosis in these cells (see Figures 
39 and 40). Caspase-3 activity was significantly increased in cells treated with gentamicin at 2 
mg/ml and was normalized by co-treatment with Cat (see Figure 41). 
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Figure 37. Staining of nuclei of iRPTC by DAPI. Apoptotic cells, detected by condensation 
and fragmentation of chromatin (Original magnification 200X) 
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Figure 38. DAPI-stained apoptotic bodies, formed in respond to gentamicin treatment    
 (Original magnification 200X and 600X) 
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Figure 39. Caspase-3 activity in iRPTC cells treated with gentamicin at the concentration 
of 2mg/ml with +/-Cat co-treatment (300U/ml). Data are presented as a percentage of 
control. Values are corrected to lysate protein levels. This experiment was done in triplicate 
and 3 experimental situations in each group were analyzed. Positive control (cells treated with 
staurosporin) was used only for quality control of the procedure and is not presented here. 
 
 
III. 7. Mitochondrial pathway is involved in gentamicin-induced 
apoptosis in vitro. ER-stress pathway involvement is unclear. 
A Western blot (WB) was performed to validate the expression of caspase-12 and Bax 
proteins, which are involved in ER-stress and mitochondrial pathways, respectively. It was 
observed that in cells treated with 2,0 mg/ml of gentamicin there was an increased expression 
of Bax protein that was slightly attenuated by Cat co-treatment. The WB for caspase-12 also 
revealed a clear overexpression of pro-caspase-12 (52kD), which was attenuated by Cat co-
treatment. However, expression of the cleaved product was not conclusive. Two cleaved 
caspase-12 products were detected with molecular weights of 37 kD and 27 kD.  
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Figure 40.  WB results for caspase-12 and Bax from cells samples treated with 
gentamicin at 2.0 mg/ml alone or co-treated with Cat (300U/ml). Quantification wasn’t 
performed due to small sample size which was not enough for statistical analysis. 
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IV. DISCUSSION. 
  IV.1. C57Bl/6 mouse is a suitable model to study gentamicin nephrotoxicity. 
Despite being a very potent antibiotic with minimal resistance development, gentamicin is 
usually considered a second line of treatment for gram-negative bacterial infections because of 
its toxicity. In cases where the use of this drug is absolutely necessary physicians try to reduce 
the duration of treatment and, whenever possible, switch to a safer antibiotic medication. 
Empirical treatment with gentamicin is usually limited to 48 hours until the culture and 
sensitivity results are available. Since gentamicin toxicity is dose-dependent, drug 
concentration is closely monitored and accurate calculations for the next dose according to 
patient body weight, renal function (creatinine clearance) and gentamicin trough level is 
mandatory. In clinical practice gentamicin doses almost never exceed 10 mg/kg.  
In the present study we demonstrated that the C57Bl/6 mouse is a suitable model to study 
gentamicin nephrotoxicity by using doses and treatment durations close to those applied in 
human cases.  
Our study revealed that gentamicin at a dose of 20 mg/kg delivered for 5 days through IP 
injections induces significant morphological changes and tubular apoptosis in the kidneys of 
treated animals. The damage persisted for at least 10 days after treatment. Gentamicin 
treatment also caused a significant weight reduction in both WT and Cat-Tg mice by the end 
of the treatment course, although weight loss was less in the Cat-Tg group. However, mice of 
both group regained their normal weight within 10 days of the end of treatment, and the Cat-
Tg group had gained an additional 1,40 (± 0.3) g to their pre-treatment body weight. 
Interestingly, the kidney weight / body weight ratio was higher in WT mice treated with 
gentamicin than the control and Cat-Tg-treated mice, and this trend persisted even 10 days 
after the treatment. The mechanism of these changes remains obscure. Studies by others have 
reported that gentamicin induces weight loss in experimental animals [23, 206, 207]. Feyissa 
et al. suggest that dehydration and metabolic acidosis due to AKI induced by gentamicin are 
the main reasons. Increased kidney weight in treated animals was explained by the edema of 
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injured kidneys. I think metabolic acidosis due to AKI might explain the weight loss in treated 
animals. WT-treated animals had decreased urine output compared to other groups, a finding 
which may reflect the severity of AKI. Gentamicin in humans causes nonoliguric and even 
polyuric renal failure because damaged tubules are not able to concentrate urine, which in turn 
promotes water loss and electrolytes disturbances; this situation rarely progresses to the 
oliguric or anuric phase. In our study both treated groups showed weight reduction, but it was 
more profound in WT animals. The kidney weight / body weight ratio in WT-treated mice was 
significantly higher than in the control mice, while the kidney/body weight ratio in treated 
Cat-Tg mice did not differ from the control group. Taken together, significant weight 
reduction, decreased urine output and a higher kidney weight / body weight ratio likely 
reflects more severe kidney damage and inflammatory swelling of the kidneys in WT-treated 
animals. These findings raise the necessity of performing more tests in order to assess kidney 
function in experimental groups and determine time points for the development of gentamicin-
induced nephrotoxicity as well as possible recovery from it. Analyzing urine and serum 
samples from treated animals (the samples were collected but have not yet been processed) 
will give us more answers on the status of kidney function in different groups. Plasma 
creatinine and BUN, two main markers of kidney function, can be validated as well as 
enzymuria, a specific feature of gentamicin-induced tubular damage.  
The dosage of 20 mg/kg of gentamicin caused significant kidney morphology changes and 
tubular apoptosis in all treated animals (total of 8) in the WT group sacrificed 24 hours after 
last injections. The damage persisted in most WT animals that were sacrificed 10 days after 
treatment (5 out of 6). PAS-staining of the kidney sections of WT-treated animals revealed 
classic findings of gentamicin-induced tubular damage: dilation of RPTs, loss of the brush-
border, damaged epithelial cells with cytoplasmic vacuoles and karyolitic nuclei, detached 
cells and cell debris, forming epithelial casts in the tubular lumen. There was no obvious 
necrosis. 
Most studies in gentamicin-induced AKI using an animal model have been performed with 
very high doses of the drug, usually more than 80 mg/kg. These doses induced acute overt 
tubular necrosis with sloughing of necrotic tubular cells into the lumen. However, it was 
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shown in humans that the term Acute Tubular Necrosis (ATN), which is used sometimes for 
ischemia or toxic-induced AKI, is actually a misnomer. Racusen et al.  [208] showed in their 
1991 study that epithelial casts from the urine of patients with post-transplant AKI contained 
viable cells. These cells excluded trypan blue, had positive staining for gamma-glutamyl 
transpeptidase-brush-border enzyme and could even be cultured. Electron microscopy of 
cultured cell monolayers confirmed differentiated proximal tubular cells in the majority of 
cells. Later, it was demonstrated that in the kidney biopsies from the deceased-donor 
transplantation (ischemic AKI) the most prominent morphological features were effacement or 
complete loss of the proximal tubule brush-border, patchy loss of tubule cells, focal areas of 
proximal tubular dilation and areas of cellular regeneration [196]. Necrosis was inconspicuous 
in this case. Similar findings were also established for cisplatin-induced renal failure [209]. 
This disparity between the severe impairment of renal function and the relatively subtle 
histologic changes in AKI had been explained by consistent findings of apoptotic tubular cells. 
Apoptosis, being morphologically more discreet than necrosis, may cause significant 
functional impairment as well. Our findings are consistent with the above description of AKI 
pathomorphology. 
Despite some of the epithelial cells in the casts being viable [208], cast formation could cause 
tubular obstruction, with subsequent increase of the pressure in the Bowman capsule leading 
to impairment of ultrafiltration and activation of tubuloglomerular feedback [210]. 
Overall, we can conclude that a C57Bl/6 mouse treated with 20 mg/kg of gentamicin for 5 
days is a good model of gentamicin-induced AKI. 
IV.2. Catalase overexpression in proximal tubules cells attenuated gentamicin-induced 
nephrotoxicity mainly by reducing ROS generation. 
Cat-Tg-treated animals showed significantly less renal damage than WT-treated animals. The 
weight loss experienced by these animals was less profound and kidney weight did not differ 
from that of the control group. Their kidney morphology was much better than the WT-treated 
animals, with less tubular dilation, more preserved RPT epithelial cells and no cast formation. 
The apoptotic study showed significant reduction in apoptotic cells in the Cat-Tg-treated 
group as compared to the WT-treated group. 
 84 
Most interestingly, our in vitro study confirmed in vivo findings: co-treatment with Cat 
promoted RPTC survival and reduced apoptosis rate. 
Using DHE staining of kidney sections we demonstrated that gentamicin treatment induced a 
considerable amount of oxidative stress. Sections of WT-treated animals sacrificed 24 hours 
after last injection showed an unequivocal increase in ROS generation. 
Decomposition of hydrogen peroxide by Cat is one of the most important mechanisms in 
protection against intracellular oxidative stress. Not surprisingly, the amount of ROS 
decreased dramatically in kidney sections of gentamicin-treated Cat-Tg mice as compared to 
WT-treated mice.  
It is well known now that oxidative stress can trigger apoptosis through many different 
pathways. In the kidney sections of mice sacrificed 10 days after gentamicin treatment the 
amount of ROS was not statistically different from that of the control. However, WT mice of 
this group still had kidney damage and tubular apoptosis. This fact may suggest that an acute 
raise in ROS has a longstanding effect, even after the insult is discontinued and can slow down 
regeneration and repair. The mechanism of this long-lasting effect is unclear. 
IV. 3. Gentamicin increases intracellular Bax concentration.  
Many groups working in the field of gentamicin nephrotoxicity have shown in their studies 
that gentamicin induces overexpression of proapoptotic protein Bax in RPTC. This 
overexpression can be attenuated by agents which have shown to be protective against 
gentamicin nephrotoxicity [24, 211, 212]. 
However, there is no satisfactory explanation for possible mechanisms of these effects. The 
only study discussing  mechanism of increase of Bax concentration is the study of  Sevrais et 
al., published in 2006 [32]. They proposed that an increased amount of Bax protein in the 
LLC-PK1 cells treated with gentamicin was a result of accumulation rather than increased 
transcription of the protein. They showed a significant increase in Bax protein by WB but 
there was no increase in Bax mRNA, suggesting the decreased degradation of the Bax protein. 
Increased content of ubiquitinated Bax was another evidence of their hypothesis. The normal 
degradation process for the Bax protein is degradation by proteasome [213, 214]. Before 
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getting processed by proteasome, Bax undego ubiquitination [215]. Therefore, accumulation 
of ubiquitinated Bax is an indicator of the inhibition of proteasomal degradation. 
 
   Bax               Ubiquitinated Bax                           Degradation by proteasome     
 
    Bax                 Ubiquitinated Bax                           Degradation by proteasome 
 
The earlier study of Horibe et al. [119] showed that gentamicin can interact with proteasome. 
This interaction can cause the inhibition of Bax degradation and might explain the findings of 
Servais et al. [32] 
Thus, decreased degradation is the main mechanism of Bax accumulation in the cells affected 
by gentamicin. In this case it is not surprising that there was no big difference in Bax staining 
between the WT and Cat-Tg groups. These findings raise other questions: Is decreased 
degradation is really the only way of Bax increase? Does increased Bax necessarily lead to 
increased apoptosis? 
In our study we observed only a slight difference in Bax expression, which was less abundant 
in Cat-Tg-treated animals sacrificed 24 hours after the last injection, although it was still 
significantly higher compared to the control group of non-treated animals. Overexpression of 
Bax was also observed in both WT and Cat-Tg mice sacrificed 10 days after last injection. 
Studies by others, which have shown a gentamicin-induced increase in Bax expression, 
demonstrated these results using Western blot [24, 211]. WB is a protein quantitative 
technique, meaning we cannot make a conclusion regarding the mechanism of protein 
increase, whether it is true overproduction or decreased degradation. On the other hand, it is 
indubitable that gentamicin induces oxidative stress and increased ROS generation. Increased 
ROS generation in turn is known to upregulate proapoptotic proteins including Bax [216]. In 
addition, as mentioned in the introduction, cathepsins released from ruptured lisosomes can 
directly activate Bid, which in turn actives Bax.  
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Another point is that an increased quantity of Bax protein does not necessary mean an increase 
in apoptosis. Conformational activation and translocation of Bax protein to mitochondrial 
membranes are the key features of Bax proapoptotic activity. It is yet unclear what induces 
Bax translocation; however, there are some data indicating that activation of p38MAP kinase 
and iNOS [217] as well as accumulation in intracellular ROS [218] can mediate this 
translocation.  
 Indeed, activation of p38 MAP kinase and the subsequent generation of iNOS as well as Bax 
overexpression induced by gentamicin have been shown by Gong et al. [211]. They also 
demonstrated that the antioxidant N-acetylcystein (NACA) prevents activation of p38 MAP 
kinase and attenuates Bax overexpression and apoptosis. 
I think it would be a valuable follow-up to our  study to examine the mRNA of Bax in the 
cortex of treated animals and in vitro in treated iRPTC. We could also study Bax translocation 
by immunoflouresence staining (in vivo) or using cell lines expressing Bax-eGFPand 
analyzing samples with confocal microscopy for Bax distribution pattern, which is described 
elsewhere [219, 220]. 
In addition, it is well established that it is a balance/ratio between pro- and antiapoptotic 
proteins that determines whether the cell will undergo apoptosis or not. Other studies have 
demonstrated that gentamicin can downregulate the expression of Bcl-2 and increase the 
Bax/Bcl-2 ratio [24, 211, 221]. Thus, we might consider adding Bcl-2 immunostaining to a 
future study. 
 87 
It is worth noting that strong Bax staining was noticed in the distal tubules of our experimental 
animals. Damage to distal tubules and collecting ducts caused by gentamicin has already been 
described before [222]. It is distal tubules damage that seems to be responsible for the clinical 
characteristics of gentamicin-induced AKI, namely nonoliguric AKI due to the loss in the 
ability of damaged distal tubules to concentrate urine. In our model, Cat-Tg mice overexpress 
Cat strictly in the proximal tubules. We cannot validate the difference in terms of the effect of 
gentamicin on distal tubules in animal groups, which is beyond the scope of this study. 
However, this might contribute to AKI in treated animals and explain why body weight loss 
was observed in both WT- and CAT-Tg-treated groups, since distal tubules of Cat-Tg mice are 
not protected by the overexpression of Cat in RPTs. 
IV. 4. Gentamicin induces Bmf expression in RPTs cells, which in turn can trigger 
anoikis of renal epithelial cells and contribute to cellular damage. 
In our study we demonstrated that gentamicin significantly increases Bmf expression in the 
RPTCs of treated animals. The Bmf expression was less prominent in the kidneys of animals 
sacrificed 10 days after the last injection; however, it was still significantly higher compared 
to the non-treated control group Bmf overexpression was attenuated in Cat-Tg mice sacrificed 
24 hours after last injection as compared to WT-treated mice. 
These interesting and novel findings definitely need further investigation in order to facilitate 
understanding of the underlying mechanisms. 
One of the possible explanations of Bmf expression induced by gentamicin is activation of 
CAP-independent translation of Bmf. It was shown by others that some Bmf isoforms, which 
have a good affinity to Bcl-2 and a potent proapoptotic effect, can be translated in a CAP-
independent manner. This means that any form of cell stress, including oxidative stress 
causing suppression of CAP-dependent translation machinery, can induce endogenous Bmf 
expression [223]. 
In our laboratory, Dr. Chan’s team demonstrated that Bmf protein and Bmf mRNA were 
upregulated in the RPTC of diabetic mice. They also showed that high glucose can upregulate 
Bmf gene expression in RPTC in vitro whereas rotenone, catalase, diphenylene iodonium and 
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apocynin can decrease it [197]. It is well known that high glucose (HG) generates intracellular 
oxidative stress [224, 225]. Attenuation of HG-induced Bmf expression by antioxidants 
proved that Bmf upregulation is mediated, at least in part, by generation of ROS and oxidative 
stress. This supports our hypothesis that gentamicin can upregulate Bmf via ROS generation 
and that activated Bmf contributes to tubular cell apoptosis. Other factors can also explain 
gentamicin-induced Bmf activation. 
The effect of ischemia on cell-cell and cell-extracellular matrix (ECM) interaction is well 
established. Ischemic injury causes a redistribution of integrins — so-called anchors of the 
cells— to the apical membrane [226]. This redistribution leads to the detachment of viable 
cells from the basement membrane with consequential cell death. This type of cell death is 
called anoikis, which is essentially apoptosis induced by inadequate or inappropriate cell-
matrix interactions. The study by Puthalakath et al. [150] suggests that activation of Bmf 
protein, which is normally sequestered by the myosin V motor complex with dynein light 
chain 2, plays an important role in anoikis. They propose that loss of cell attachment or any 
other insults to the cytoskeleton leads to he release of Bmf , which can bind Bcl-2 and prevent 
its antiapoptotic activity. The role of Bmf in anoikis has also been demonstrated in many other 
studies [152, 227, 228]. 
The question is how gentamicin can cause a disturbance in cell/EMC interaction and trigger 
anoikis. It was previously shown that gentamicin has a vascular effect and induces a reduction 
in renal blood flow [171, 229]; in this way, gentamicin can cause some kind of tubular 
ischemia. As discussed above, ischemia can affect tubular cells integrins, disturb cell/EMC 
interaction and activate proapoptotic activity of Bmf. Another mechanism by which 
gentamicin can release Bmf from sequestration is gentamicin’s recently discovered ability to 
bind with CLIMP-63 [53]. The function of this protein is not yet well established, but it is 
thought to be an anchoring protein connecting the ER to the cytoskeleton [230]. Gentamicin 
can affect the stability of the cytoskeleton by binding with CLIMP-63 and triggering Bmf 
release.   
It is also interesting to note that other studies have shown that anoikis can proceed though the 
intrinsic pathway. In mammary epithelial cells, Bax translocates from the cytosol to the outer 
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mitochondrial membrane (OMM) within 30 minutes of loss of ECM attachment [231]. This 
finding correlates with our observation of strong positive immunostaining for Bax and Bmf in 
detached RPTC cells.  
IV.5. Caspase-12 role in gentamicin-iduced tubular damage remains uncler. 
The role of Caspase-12 in apoptosis remains uncertain. While some studies suggest the 
caspase-12–dependent pathway plays a strong role in apoptosis [98, 102], others disprove this 
theory [104, 109]. 
Previously, our laboratory has shown that hyperglycemia and albuminuria induces Casp12 
overexpression and Casp-12 activity and subsequent apoptosis in RPTS of diabetic mice via 
ROS. Cat-Tg diabetic mice overexpressing catalase (CAT) in their RPTCs exhibited 
attenuated Casp-12 overexpression and tubular apoptosis. It was also shown that Cat-
overexpression in RPTs of diabetic mice attenuates Casp12 overexpression and subsequent 
tubular apoptosis, induced by high glucose and albumin [232].  
In the present study we performed IHC for Casp12 and Casp12 activity ex vivo in isolated 
RPTCs of experimental animals. These studies showed significant elevation of caspase-12 
overexpression in treated animals sacrificed 24 hours and 10 days after last injections and 
increased activity of Casp12 in gentamicin-treated mice sacrificed 24 hours after treatment. 
There was significant attenuation of Casp12 immunostaining in the Cat-Tg-treated group 
compared to WT-treated animals. However, Cat overexpression in RPTs seemed to not affect 
Casp12 activity in Cat-Tg mice treated with gentamicin. WB perfomred in immortalized rat 
RTCs (iRPTC) showed overexpression of pro-caspase-12 in both cell groups, those treated 
with gentamicin alone and those co-treated with Cat. However, there was no corresponding 
increase in the cleaved active form of Casp12. Unfortunately, these data do not allow us to 
draw any conclusions about the role of Casp12 in gentamicin-induced tubular damage, since 
the experiment was performed only once. 
I believe performing Casp12 mRNA quantification in isolated RPTCs from experimental 
animals as well as running Western blot would bring more value to the study. Gentamicin can 
induce Casp12 overexpression and activation through at least two different pathways: first, by 
causing oxidative stress and generation of ROS, which subsequently lead to ER-stress; and 
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second, by inducing misfolding of proteins through the inhibition of certain chaperones [119] 
and, possibly, by alteration of protein synthesis[120]. In the present study we demonstrated 
that overexpression of Cat in RPTCs can attenuate ROS generation induced by gentamicin. 
However, catalase might not protect from the inhibitory effect of gentamicin on chaperones or 
and its ability to bind to eukaryotic ribosomes ,alter protein synthesis and induce ER-stress. 
This may explain high levels of Cas12 activity in Cat-Tg-treated mice. Nevertheless, Cat-Tg 
mice exhibit a significant reduction in tubular damage and apoptosis, which allows us to 
conclude that Casp12 activation is not the main pathway in gentamicin-induced tubular 
toxicity. We can also study this in vitro by transfecting iRPTC cells with caspase-12 small 
interfering RNA (siRNA) and then treating the transfected cells with gentamicin. Failure to 
show a reduction in apoptosis of transfected cells would indicate the insignificant role of 
Casp12 in gentamicin-induced RPTC apoptosis. 
Our pilot study has added even more mystery to the already enigmatic caspase-12 protein. 
Knowing that gentamicin can overcome stop-codons, we tried to detect the caspase-12 protein 
in gentamicin-treated human primary RPTCs (hRPTCs). For these studies we used several 
concentrations of gentamicin (from 0.5 to 5 mg/ml) and cells were harvested 24 hours after 
treatment .We were very surprised that WB showed full-length and cleaved caspase-12 not 
only in treated but also in controlled cells. We then sent the DNA of hRPTCs for sequencing, 
which showed the absence of premature stop-codons but the presence of catalytic box 
mutation (see Supplemental data). These data, after better analysis and confirmation of the 
findings, suggest that caspase-12 structure and function in humans needs further extensive 
study. 
V. CONCLUSION. 
Overall, our data suggest that oxidative stress and ROS generation play a crucial role in 
gentamicin-induced nephrotoxicity and can be placed high up in the hierarchy of the 
intracellular events triggered by intracellular gentamicin accumulation. This oxidative stress 
may have a long lasting effect. Cat, as a potent antioxidant, attenuates oxidative stress and 
protects RPTs against gentamicin toxicity. 
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VI. STRONG AND WEAK POINTS OF THE CURRENT STUDY. 
VI.1. Strong points: 
- In our study we used a lower dose of gentamicin compared to most other studies in the field. 
It is known that low and high doses of gentamicin have different effects on the kidneys. By 
using a lower dose of gentamicin for our animals, we approached more closely human settings 
and thus improved the relevance of our study. 
- In this study we found Bmf protein as a new participant in gentamicin-induced RPTC 
damage. We also demonstrated that gentamicin induces Casp12 overexpression and activity. 
However, the role of Casp12 in gentamicin-induced apoptosis needs to be clarified. 
- Recentlymany molecular mechanisms and pathways of gentamicin-induced nephrotoxicity 
have been elucidated in other studies. However, the hierarchic relationships among them 
remains unknown. We demonstrated that Cat overexpression in RPTCs attenuates tubular 
damage caused by gentamicin. This finding allows us to conclude that oxidative stress can be 
placed high up in the hierarchy of the events, induced by gentamicin in RPTCs. 
            VI.2. Weak points: 
- Initially, to establish the gentamicin dose for the first pilot experiments, we choose to 
sacrifice animals 10 days after last injections and subsequently chose doses of 20 mg/kg, since 
lower doses fail to demonstrate any morphological changes or apoptosis. Further study 
showed that 10 days after the treatment is not the best time point to estimate gentamicin 
toxicity. Mice sacrificed 24 hours after a five-day course of gentamicin had more severe 
changes, significant apoptosis and casts formation. I think that the day after the last injection 
marks a good representation of maximal kidney damage. It would be interesting as well to use 
10 mg/kg for 5 days and sacrifice animals 24 hourse after treatment to observe the effect of 
this gentamicin dose. This way we might achieve our goal of studying gentamicin –induced 
nephrotoxicity when gentamicin is used in a therapeutic range. 
 
 92 
- High variability in kidney damage can be observed when low doses of gentamicin are used. 
Increasing the sample size would add more power to the study. Ten to twelve animals per 
group would be a better sample size for the study. 
 
- Immunohistochemistry, performed for Bax, Bmf and Casp12, is an important tool to show 
the overexpression of the protein and the location of the overexpression, since our focus is on 
RPTCs. However, immunohistochemistry is probably not ideal for the quantification of 
overexpression. Existant data empowered by mRNA and Western blot on isolated RPTCs 
from experimental animals would make our study more solid 
 
VII. FUTURE EXPERIMENTS. 
vii.1. Serum gentamicin levels can be measured from the serum collected at the time of the 
animal’s sacrifice. This serum obviously can be used only for the animals which were 
sacrificed 24 hours after last injection and will represent gentamicin trough levels. If new sets 
of animals are treated, we could measure gentamicin trough levels before 3d or 4th dose and 
then 24 hours after the last dose. 
vii.2. A kidney function study measuring serum creatinine or urea. Decreased urinary output in 
WT-treated animals may reflect significant AKI. Elevated creatinine or urea levels would 
confirm this hypothesis. 
vii.3. To elucidate the  molecular mechanism of gentamicin nephrotoxicity, I would give 
priority to the following experiments: 
a) It would be a valuable addition to our data to study the mRNA of Bax in the cortex of 
treated animals and in vitro in gentamicin-treated iRPTC. Increased Bax mRNA would 
indicate that gentamicin not only decreases Bax degradation but also induces Bax 
overexpression, most likely via oxidative stress. We could also study Bax translocation by 
immunoflouresence staining (in vivo) or by using cell lines expressing Bax-eGFP for an in 
vitro study showing the effect of gentamicin on Bax activation and the induction of apoptosis. 
IHC of kidney sections for Bcl-2, if demonstrate decrease of Bcl-2 expression in treated 
animals, would contribute to our understanding of gentamicin-induced apoptosis. 
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b) Gentamicin-induced overexpression of Bmf is a novel finding. Transcriptional upregulation 
of Bmf has been reported to be induced by several stressors, and oxidative stress is one of 
them. Attenuation of this overexpression in Cat-Tg animals supports this hypothesis. I would 
like to perform a quantification of Bmf mRNA in isolated RPTC of experimental animals and 
in cell cultures treated with gentamicin to confirm transcriptional upregulation. In order to 
promote apoptosis, Bmf, which is normally sequestered to the actin cytoskeleton-based 
myosin V motor complex, should be released. Possible mechanisms by which gentamicin can 
induce RPTCs’ detachment from the basal membrane and subsequent Bmf release is a very 
interesting area of research, but lies beyond the scope of the current study. 
c) The role of Casp 12 in gentamicin-induced apoptosis remains unclear. It seems that 
gentamicin definitely increases both expression and activity of Casp12; however, it is not clear 
yet if Cat can normalize Casp 12 activation or if Casp12 overexpression and activation plays a 
significant role in tubular apoptosis. Western blot done on the isolated RPTCs from 
experimental animals as well as mRNA quantification would add more value to the existing 
data. With a Western blot we could analyze Casp12 activation by observing cleaved forms. 
We probably would need to also repeat the Casp 12 activity study with more samples. In vitro 
experiments with caspase-12 siRNA would help to establish the role Casp12 in gentamicin-
induced apoptosis. 
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Supplemental data 
 
 
 
Figure 1. hRPTC treated with different concentration of gentamicin, showing  concentration-
dependent increase in full length Casp12 protein (52kD). Protein product of 37kD which is 
consistent with cleaved Casp12 protein was also detected. 
 
 
 
ii 
Absence of premature stop-codon mutation  in hRPTC (sequenced with reverse Primers)
1gtgtacatgatttcattctgttcactttgttatgtcaaaaagaagaaaacaccttctgct 
61tcctattttccaaaggaaagcagttatacacgagatcagagtctaattttatcttggcaa 
121agaaaaagagaatttgaggactgggaattttccattcagggtaatatcaacaagctggtc 
181cactgagaggagagcaagcctgttgaaattgtttttgctttcacagctttttcctgtccg 
241gggagcaggagaagccatggctgatgagaaaccatccaacggtgttctggtccacatggt 
301gaagttgctgatcaagacctttctagatggcatttttgatgatttgatggaaaataatgt 
361gttaaatacagatgagatacaccttataggaaaatgtctaaagtttgtggtgagcaatgc 
421tgaaaacctggttgatgatatcactgagacagctcaaattgcaggcaaaatatttaggga 
481acacctgtggaattccaaaaaacagctgagttcagatatatccagtgatggagaaagaga 
541ggcgaacatgcctggcctcaacatccgcaacaaagaattcaactatcttcataatcgaaa 
601tggttctgaacttgaccttttggggatgtgagatctacttgaaaaccttggatactcagt 
661ggttataaaagagaatctcacagctcaggaaatggaaacagcactaaggcagtttgctgc 
721tcacccagagcaccagtcctcagacagcacattcctggtgtttatgtcacatagcatcct 
781gaatggaatctgtgggaccaagcactgggatcaagagccagatgttcttcacgatgacac 
841catctttgaaattttcaacaaccgtaactgccagagtctgaaagacaaacccaaggtcat 
901catcatgcaagcctgccgaggcaatggtgctgggattgtttggttcaccactgacagtgg 
961aaaagccagtgcagatactcatggtcggctcttgcaaggtaacatctgtaatgatgctgt 
1021tacaaaggctcatgtggaaaaggacttcattgctttcaaatcttccacaccacataatgt 
1081ttcttggagacatgaaacaaatggctctgtcttcatttcccaaattatctactacttcag 
1141agagtattcttggagtcatcatctagaggaaatttttcaaaaggttcaacattcatttga 
1201gaccccaaatatactgacccagctgcccaccattgaaagactatccatgacacgatattt 
1261ctatctctttcctgggaattaaaactcataagaagcaactcaggt 
Primers sequence
Mutation sequence
Sequence of the human truncated of Casp12  
 
Figure 2. Sequensing of the CASP12 fragment from isolated hRPTC’s DNA shows absence 
of premature stope codone at the position 629-631. 
 
 
iii 
Catalytic-box mutation in hRPTC (SHG instead of SHS)
Primers sequence
Mutation sequence
Supposed location of 
Premature Stop Codon
1gtgtacatgatttcattctgttcactttgttatgtcaaaaagaagaaaacaccttctgct 
61tcctattttccaaaggaaagcagttatacacgagatcagagtctaattttatcttggcaa 
121agaaaaagagaatttgaggactgggaattttccattcagggtaatatcaacaagctggtc 
181cactgagaggagagcaagcctgttgaaattgtttttgctttcacagctttttcctgtccg 
241gggagcaggagaagccatggctgatgagaaaccatccaacggtgttctggtccacatggt 
301gaagttgctgatcaagacctttctagatggcatttttgatgatttgatggaaaataatgt 
361attaaatacagatgagatacaccttataggaaaatgtctaaagtttgtggtgagcaatgc 
421tgaaaacctggttgatgatatcactgagacagctcaaactgcaggcaaaatatttaggga 
481acacctgtggaattccaaaaaacagctgagttcagatatatccagtgatggagaaagaga 
541ggcgaacatgcctggcctcaacatccgcaacaaagaattcaactatcttcataatcgaaa 
601tggttctgaacttgaccttttggggatgcgagatctacttgaaaaccttggatactcagt 
661ggttataaaagagaatctcacagctcaggaaatggaaacagcactaaggcagtttgctgc 
721tcacccagagcaccagtcctcagacagcacattcctggtgtttatgtcacatagcatcct 
781gaatggaatctgtgggaccaagcactgggatcaagagccagatgttcttcacgatgacac 
841catctttgaaattttcaacaaccgtaactgccagagtctgaaagacaaacccaaggtcat 
901catcatgcaagcctgccgaggcaatggtgctgggattgtttggttcaccactgacagtgg 
961aaaagccggtgcagatactcatggtcggctcttgcaaggtaacatctgtaatgatgctgt 
1021tacaaaggctcatgtggaaaaggacttcattgctttcaaatcttccacaccacataatgt 
1081ttcttggagacatgaaacaaatggctctgtcttcatttcccaaattatctactacttcag 
1141agagtattcttggagtcatcatctagaggaaatttttcaaaaggttcaacattcatttga 
1201gaccccaaatatactgacccagctgcccaccattgaaagactatccatgacacgatattt 
1261ctatctctttcctgggaattaaaactcataagaagcaactcaggaaaatgaaggcattat 
1321ggtgtctatgaatctgctattagaaaaggtcaatttttgattaagaatatttttatacca 
1381aactgctcagctgtccaccttttcaaataccaggctaaaatcaatctcatatttttgcta 
1441aattaatgcttaataaatttttattataaaattgtgcttgttttctaattttgtcataaa 
1501ttaagtcatgcttataggagaaaaaattaagtattaaaaatcataaaaaatgaagaaata 
1561atcatcatcaacctttttaaaactattcataaaaactcaagttttttatatagcttattt 
1621attttgtatatccaattttgtgtgcttttattatattgttataacattactactagtaat 
1681aaaactat 
Sequence of the human full-length 
Casp12
 
Figure 3. Sequensing of the CASP12 fragment from isolated hRPTC’s DNA shows mutation 
in the catalytic box of CASP12.  
